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Abstract 
Background:  Alzheimer’s disease (AD) is the most common of the dementia disorders, and age is the 
main risk factor. In Norway, there are approximately around 60 000 demented persons, and the 
prevalence is expected to increase more than twofold over the next 40 years. AD is a 
neurodegenerative disease, and the pathology probably starts many years before the onset of 
symptoms. Early diagnosis has to an increasingly extent come into focus of AD research. There is the 
comprehension that drug intervention, when available, should start at an early phase of the disease, 
before extensive irreversible neuronal damage occurs. Biomarkers of the disease can be measured in 
vivo, and are associated with specific features of the pathophysiological processes. Cerebral glucose 
metabolism and amyloid depositions measured by positron emission tomography (PET) are such 
biomarkers, and the aim of this review is to evaluate these in early Alzheimer’s disease.  Results from 
the most important longitudinal PET studies of subjects with mild cognitive impairment are collected 
and compared, and the ability of baseline PET measurements to predict future conversion to AD or 
cognitive decline is of special interest. 
Methods: Literature study based on non-systematic search in the PubMed database. 
Main results: 18F-fluoredeoxyglucose PET measurements are able to predict future AD with 
accuracies ranging from 56 – 90 %, sensitivities from 57 – 93% and specificities from 47 – 91%. 
Retention of the amyloid binding 11C-Pittsburgh compound B (PiB) predicts AD with accuracies 
ranging from 65 – 87 %, sensitivities from 93 – 100 % and specificities from 56 – 81 %. Patterns of 
glucose hypometabolism and amyloid depositions are rather consistent in the different studies. 
Concluding remarks: Some of the longitudinal studies achieved good accuracies and show that AD 
can be diagnosed in an early phase using PET.  
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1 Introduction 
Alzheimer’s disease (AD) is the most common of the dementia disorders, accounting for more than 
70 % of the cases, and age is the main risk factor. In Norway, there are approximately around 60 000 
demented persons, and the prevalence is expected to increase more than twofold over the next 40 
years (1). The disease is therefore expected to become a major public health concern. The disease is 
life changing for the individuals affected and their families. Slowly the patients lose their memory 
and cognitive function, and also their personality change. For the time being, there is no medical 
therapy that can stop or reverse the neurodegenerative development, but several clinical trials are 
on-going (2). 
At a histopathological level, AD is characterized by the presence of amyloid plaques, neurofibrillary 
tangles, activated microglia and neuronal cell loss. Macroscopically there is atrophy in certain brain 
areas including the temporal and frontal lobes, due to degeneration of synapses and neuronal cell 
death. The diagnosis is not definite until post-mortem neuropathologic assessment is performed and 
requires the presence of amyloid deposits and neurofibrillary tangles in the hippocampus and 
neocortex. The pathogenesis is not fully understood, but according to the amyloid cascade 
hypothesis, the deposition of amyloid β peptides (Aβ) leads to neuronal dysfunction and subsequent 
death. The Aβ peptides are the results of cleavage of the amyloid precursor protein (APP), which is a 
transmembrane glycoprotein, into Aβ1-40, Aβ1-42 and Aβ oligomeres. The Aβ1-42 aggregates more easily 
than Aβ1-40, and is more associated with the disease. The ratio of these two isoforms is a result of the 
pattern of cleavage of APP by α, β and γ secretases. Amyloid plaques are extracellular deposits of 
fibrils and amorphous aggregates of Aβ, but also diffuse plaques are present to a large extent. The 
amyloid cascade hypothesis suggest that toxic levels of Aβ concentration triggers the formation of 
intracellular tangles of hyperphosphorylated tau protein, but the pathway between plaques and 
tangles is not clearly understood (3). Also alterations in glial cells are seen. 
 Aβ is thought to damage synapses and neurites. Especially neuronal circuits involved in learning and 
memory seem vulnerable to the pathologic processes in AD. There is seen loss of neurons in the 
entorhinal cortex, hippocampus, frontal, parietal and temporal cortices in AD patients, but this 
occurs over a time period of many years, and probably starts long before symptoms occur. Genetics 
is estimated to account for around 70 % of the risk of developing AD, and the most consistently 
associated risk gene is apolipoprotein E (ApoE). Homozygotes of the ε4 variant are more than 7 times 
more likely to develop the disease than those with ApoE ε3 alleles (2).  
The last decade, early diagnosis of AD has to an increasingly extent come into focus. There is the 
comprehension that drug intervention, when available, should start at an early phase of the disease, 
before extensive irreversible neuronal damage occurs. In this context, many research studies have 
examined the ability of different biomarkers to diagnose AD at different stages of the disease and to 
monitor disease progression. The biomarkers are parameters that can be measured in vivo, and that 
are associated with specific features of the pathophysiological processes. Both fluid and imaging 
measures are included in the term, and most commonly in the AD context are protein levels in 
cerebrospinal fluid, brain atrophy as measured by structural magnetic resonance imaging (MRI) and 
glucose hypometabolism and amyloid depositions as measured by positron emission tomography 
(PET). Very recently, biomarkers were incorporated in the new recommendations on diagnostic 
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guidelines of the American National Institute on Aging (NIA)(4). Also the pre-dementia stages of AD 
are included in the new guidelines, reflecting the fact that AD dementia is the end stage of several 
years of pathological processes and increasing brain damage. The pre-dementia phases include the 
pre-clinical phase, in which no symptoms have yet occurred, and the mild cognitive impairment (MCI) 
phase, in which there most often are symptoms of reduced episodic memory and possibly other 
cognitive functions, but activities of daily living are not affected. The dementia phase is when also 
activities of daily living are interfered. The recommendations for the pre-clinical phase are intended 
for research purposes only. Similarly, an international working group revised the research criteria for 
the diagnosis of AD a few years ago, also incorporating biomarkers as supportive criteria (5). It is 
emphasized that there is need of further research to validate the application of biomarkers, for 
instance more biomarker comparison studies, studies on the combination of biomarkers, more post-
mortem studies and standardization of criteria defining abnormal and abnormal findings (4). 
Several large, longitudinal multi-site studies started some years ago, measuring several biomarkers in 
the same subjects, in order to get a wider knowledge about such issues. The first project was the 
Alzheimer’s Disease Neuroimaging Initiative in North-America, which started in 2004 and enrolled 
1000 volunteers at 59 centers. Standardizing the measurement and imaging techniques has also 
been one of the goals. Researchers worldwide can apply and get access to the extensive database of 
biomarker measurements. Later, similar projects were initiated in Australia, Europe, Japan and 
elsewhere (6). 
PET measures emissions from radioactively labeled tracers that have been injected into the 
bloodstream. Using the radiolabelled glucose analogue 18F-fluorodeoxyglucose (FDG), cerebral 
glucose metabolism is measured. The variation in uptake of FDG at different regions of the brain 
supposedly mirrors differences in levels of neurosynaptic activity. It has been shown that specific 
patterns of hypometabolism is connected to AD pathology (7) 
The 11C-labelleled PET tracer Pittsburgh compound B (PiB) seems to bind to fibrillary amyloid β with 
high affinity, and makes it possible to image amyloid plaques. 11C-PiB is the most widely used amyloid 
tracer, but the short half-life of only 20 minutes of 11C demands an on-site cyclotron for production 
of the isotope, and this prevents widespread clinical use. The physical half-life of 18F is 110 minutes, 
which makes it possible to produce 18F-labelled tracers off-site and ship to the PET-centers. Three 
such tracers for amyloid imaging are currently being investigated in clinical trials, namely florbetapir, 
florbetaben and flutemetamol. They are developed as proprietary tracers for commercial distribution 
(8). 
The aim of this review is to evaluate cerebral glucose metabolism and amyloid depositions as 
biomarkers in early Alzheimer’s disease.  Results from the most important longitudinal PET studies of 
MCI subjects are collected and compared, and the ability of baseline PET measurements to predict 
future conversion to AD or cognitive decline has been of special interests. If additional biomarkers 
were measured in these studies, those results are also described. In order to rule out a possibly 
important source of error, also longitudinal studies including post-mortem assessment are reviewed. 
Such studies can tell whether there is correspondence between imaging findings and actual 
neuropathology seen in Alzheimer’s disease. Finally, the PET methods are briefly compared with MRI 
methods.   
5 
 
2 Methods 
A literature search was done in PubMed. Also the Cochrane database was searched, but only a few 
irrelevant studies were found. The search design was set up to include articles of PET studies in either 
AD or MCI patients, and the search was limited to studies performed in humans, to articles written in 
English and were published after 2004: 
("Alzheimer Disease"[Mesh] OR "mild cognitive impairment") AND "Positron-Emission 
Tomography"[Mesh] 
Limits: Humans, English, Publication Date from 2005/01/01 to 2011/08/30 
This resulted in 635 articles. A primary sorting of these based on their abstracts was performed, 
based on following exclusion criteria: - samples of less than 30 subjects in total or less than 20 MCI subjects - no PET imaging, only MRI or CSF measurements - emphasis on image processing or evaluation of different statistical methods - emphasis on monitoring treatment effects - emphasis on subcategories of AD patients 
Then 206 articles remained. In this selection, several sub-searches were performed to find studies 
involving the different PET tracers like FDG, PiB, florbetapir, florbetaben, flutemetamol or FDDNP. 
Also searches for “longitudinal” were performed in the different sub-selections. Articles of 
longitudinal studies published most recently were read first, since these often contained references 
to other similar studies. If such studies were not in the selection, they were included. 
The sub-selection of FDG PET studies was analyzed first. The original idea was to exclude studies with 
less than 30 MCI subjects, but gradually it became evident that rather few studies would remain for 
analysis. So this criterion was changed to include studies of more than 25 MCI subjects. In the 
comparison of post-mortem studies, studies of more than 20 MCI or AD subjects were included, and 
here also studies going back to year 2000 were included, in order to get a selection of a certain size. 
Likewise, the criteria were modified for the analysis of longitudinal PiB PET studies as well. There 
were even less of these studies, and the inclusion criterion was studies of more than 20 MCI subjects. 
Post-mortem studies are rare, and most case-studies published were briefly described. For the other 
18F-labelled amyloid tracers, there are not published longitudinal studies of MCI subjects. One post-
mortem study is published, of florbetapir. For each tracer category, also the largest cross-sectional 
study with MCI subjects is described, because this gives valuable information about what brain 
regions are involved for the different PET tracers.  
There has been research in the field of FDG PET imaging of AD patients for nearly three decades, and 
limiting the search selection to studies published after 2004 probably excluded several interesting 
studies. Nevertheless, it was considered that general inclusion criteria were preferred in order to get 
a reasonable amount of studies, and one would assume that the later studies benefit from 
development in image processing and analytical methods. Limiting the number of articles to those 
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published after 2004 will ensure that longitudinal studies of the larger multi-site projects like ADNI 
were be included. 
3 Results 
3.1 PET with 18F-Flurodeoxyglucose  
Several studies the last decades have been investigating the pattern and degree of cerebral glucose 
metabolism reductions in connection with AD pathology at different stages. It has been shown that 
the uptake of the tracer 18F-fluorodeoxyglucose is significantly reduced in certain brain areas years 
before the onset of AD symptoms in predisposed individuals, and the extent and topography 
correlate with symptom severity and predict histopathologic findings (9).  The posterior cingulate and 
the parieto-temporal cortices become early involved, while frontal cortices show reduced glucose 
metabolism later in the disease progression. Hemispherical asymmetries often occur. The 
cerebellum, the sensorimotor cortex, thalamus and pons are mainly unaffected (10). 
Quite recently, baseline results of the large multi-site study ADNI was published (11). FDG PET images 
from 82 normal controls, 142 amnestic MCI patients and 74 AD patients were analyzed and 
compared. Both the AD and MCI group had significantly lower glucose metabolism in precuneus, 
posterior cingulate and parietotemporal regions, but also the occipital and frontal cortices. Within 
the normal controls, the ApoE ε4 carriers had lower metabolic rate than non-carriers in bilateral 
precuneus and left frontal cortex. The ApoE ε4 carriers within the MCI group showed 
hypometabolism in an extensive region of the right temporal cortex. Small differences were found 
between the ApoE ε4 carriers and non-carriers within the AD group. They also found that the 
regional hypometabolism was correlated with the clinical disease severity in terms of CDR and MMSE 
scores. When analyzing the AD group separately, significant correlations were found between lower 
MMSE score and lower FDG uptake in the left frontal and temporal cortex, fusiform gyrus and 
striatum.  
3.1.1 Longitudinal FDG PET studies including post-mortem neuropathologic assessment 
There are a few longitudinal studies done with follow-up until death and autopsy is performed. From 
this literature search and another review, five such studies with more than 20 subjects were found 
(12). The studies are described below, and results are summarized in table 1. 
A large multicenter study by Silverman et al followed 138 patients for a period of 2 to 9 years (13). 
They underwent clinical evaluation for dementia, FDG-PET scan and neuropathologic examination 
after death. Due to lack of uniformity of procedures among the contributing sites, standardized 
clinical rating of dementia severity was only obtained for 79 of the subjects. Of these, 70 % were 
mildly impaired (questionable or mild dementia) at the time of the initial evaluation. The scan results 
were classified by two independently working nuclear medicine physicians, blinded to the 
pathological or clinical information. The classifications of the images as AD positive or negative were 
concordant in 94 % of the cases. The autopsies took place on average 2.9 years after the PET scan. 
Ninety-seven had findings which were classified as being positive for AD, and only 8 of these had co-
morbid conditions. Twenty-three were positive for other neurodegenerative diseases than AD, 
including frontotemporal dementia, dementia with Lewy bodies, Creutzfeldt-Jacob disease, 
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progressive subcortical gliosis, progressive supranuclear palsy and lipofuscinosis. In 18 subjects, no 
neurodegenerative disease was found. 
FDG-PET correctly identified the presence or absence of AD in 88 % of the cases, with a sensitivity of 
94 % and a specificity of 73 %. Also a subgroup of 55 patients was analyzed, with questionable or 
mild dementia at the time of the PET scan. The sensitivity and specificity of FDG-PET was 95 % and 71 
% for this subgroup, and the same accuracy was achieved when identifying AD at an earlier stage. 
In a study of Foster et al, 45 subjects were studied retrospectively based on clinical summaries and 
PET scans (14). There were only two groups, consisting of 31 with AD and 14 with FTD. Some co-
morbidity was revealed in the neuropathologic assessments. Six neurologists visually rated the FDG 
PET images after brief training. They knew the diagnosis was either AD or FTD, and though 5 % of the 
images could be rated as normal, this was not an option. Glucose metabolism was reduced in frontal, 
anterior cingulate and anterior temporal regions in FTD subjects, and in temporoparietal and 
posterior cingulate regions in AD subjects. Significant hemispheric asymmetry was seen in 
approximately half of both AD and FTD cases, and the right hemisphere was more often 
hypometabolic in the AD subjects. Also clinical summaries were evaluated independently from the 
PET images. The accuracy of the initial clinical evaluation of 79 % improved to 90 % after considering 
the PET scans. FDG PET alone correctly classified the subjects with 98 % sensitivity and 73 % 
specificity.  
Jagust et al followed a group of 44 subjects, mostly selected from a university dementia clinic (15).  A 
few were recruited from the community as control subjects. They underwent two clinical evaluations 
and one FDG PET scan in between. The median time between the initial evaluation and the PET scan 
was 0.3 years, and between PET scan and autopsy was 3.6 years.  
Diagnoses were assessed at multi-disciplinary conferences, and included AD, dementia with Lewy 
bodies (DLB), frontotemporal lobar degeneration (FTLD), vascular dementia, both AD and vascular 
dementia, cognitively impairment but not dementia (CIND), normal and unknown condition. FDG-PET 
scans were categorized as AD or non-AD by two experienced raters, blinded to clinical diagnosis. 
Done independently they agreed on 73 % of the cases, and consensus ratings were done in those 
subjects where they differed in diagnostic category. Neuropathologic examinations performed after 
death verified that the sample was a heterogeneous group. Twenty-five subjects were AD positive 
(defined by Consortium to Establish a Registry of Alzheimer’s Disease - CERAD “definite” or 
“probable” AD), including six subjects with both cerebrovascular disease and AD. Nineteen were AD 
negative, but only two were normal. The others were diagnosed with cerebrovascular disease, 
possible AD, DLB, FTLD, leukoencephalopathy and alcoholic encephalopathy. 
FDG-PET predicted the outcomes with a sensitivity of 84 % and specificity of 74 %. This was better 
than the initial clinical evaluation (sensitivity 76 %; specificity 58%) and at about the same level as the 
final clinical evaluation which took place almost 4 years later (sensitivity 88 %; specificity 63 %). The 
positive predictive value of an initial clinical AD diagnosis increased from 70 % to 84 % if also the FDG 
PET image was interpreted as positive for AD. The negative predictive value increased from 65 % if 
the diagnosis initially was not AD to 83 % if also the FDG PET image was negative. 
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In an early study, by Minoshima et al, 10 subjects with AD, 7 subjects with a Lewy body variant of AD 
and 4 subjects with diffuse Lewy bodies disease (DLBD) were investigated retrospectively (16). 
Clinically 18 subjects had received a probable AD diagnosis, some with also extrapyramidal signs, and 
3 had received a diagnosis of Parkinson’s disease. PET images were analyzed by an automated ROI-
based method. The autopsy confirmed that AD only patients had metabolic reductions in lateral 
parietal, temporal and frontal association cortices as well as posterior cingulate cortex. The patients 
with dementia of Lewy bodies, including those with co-morbid AD, showed significant reduced 
glucose metabolism in the occipital lobe, and particularly primary visual cortex, but also in the lateral 
association and posterior cingulate cortices, similar to AD. Based on glucose metabolism in primary 
visual cortex, FDG PET could distinguish pure AD patients from the DLB patients with sensitivity 90 % 
and specificity 80 %. 
Another early study was described by Hoffman et al (17). It included 22 individuals with memory loss 
or dementia which was difficult to characterize. They were all patients at a memory clinic, and they 
were followed up to 7 years.  Three of the patients had only biopsy taken and are excluded from the 
test results calculated here. Nineteen of them eventually underwent an autopsy for a pathologic 
diagnosis. FDG-PET scans were taken on average 30 months before.  The images were visually graded 
by an experienced nuclear medicine physician, who was blinded for the clinical diagnoses.  The final 
diagnoses included Creutzfeldt-Jacob disease, neuronal degeneration, Lewy body disease, 
progressive supranuclear palsy, Parkinson’s disease and mesio-limbo cortical dementia in addition to 
AD. By FDG PET images, the subjects were classified as AD or non-AD with a sensitivity of 88 %, 
specificity of 67 % and overall accuracy of 82 %. The clinical evaluation had the same sensitivity, but a 
specificity of 100 %. These numbers are derived on a small sample size, and especially the non-AD 
group is small with only 6 subjects, which limits the statistical confidence of the specificity.  
A small study was described recently by Mosconi et al (18). The sample consisted of only 7 subjects, 
but it is worth mentioning because of its qualitative information. Initially it was four normal subjects 
and three with mild AD. The follow-up time was long, up to 19 years, and the subjects underwent 2 – 
4 PET scans each. The PET images were compared to a reference normal database of 55 normal 
controls. Two of the subjects with normal status at baseline declined to MCI, and the other two 
normal subjects declined to AD. In these four initially normal subjects it was possible to detect 
significant reductions in glucose metabolism in the hippocampus while they still had the diagnostic 
status as normal and up to 7 years before they received the MCI diagnosis. At that stage, also the 
parietotemporal and posterior cingulate cortices were involved. AD was then developed one and two 
years after the MCI diagnosis in two of the initially normal subjects. Glucose hypometabolism in the 
frontal cortex was only seen in one AD subject. For all subjects the decline in glucose metabolism 
correlated with dementia severity in life and pathological diagnosis of AD. Those with the clinical MCI 
diagnosis were classified as possible AD by autopsy (CERAD), one of them also with Parkinson’s 
disease. The patients with clinical diagnosis AD at the last evaluation was confirmed as definite AD 
(CERAD).  
An aggressive and rare variant of AD, early onset familiar AD due to a gene mutation MET146Val 
PSEN1, was studied in a Swedish-Finnish family by Schöll et al and published recently (19). Only two 
carriers were followed, but this study anyhow provides some valuable insight. Several PET scans 
monitored a rapid cognitive deterioration, and eventually post-mortem examinations were done. 
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Along with clinical decline, as measured with several neuropsychological tests, it was measured 
increasingly hypometabolism in almost all the predefined ROIs, especially posterior cingulate, 
parietal and parietotemporal cortices. The levels were significantly lower than the mean of an AD 
reference group. Similarly, the quantitative levels of neurofibrillary tangles and neuritic plaques were 
significantly higher in these two subjects at post-mortem examination compared to brain tissue of 
AD patients from a brain bank. The FDG uptake values at the last PET scans, taken 4 and 5 years 
before death, correlated significantly with the amount of neuritic plaques in corresponding brain 
areas, but not with neurofibrillary tangles.  
In table 1, the capability of FDG PET as a diagnostic test for AD in some of the abovementioned 
studies is summarized. 
Table 1. Results from longitudinal FDG PET studies with autopsy as gold standard. 
Study N Pathologic 
diagnosis 
Time from  
PET to 
autopsy 
(years) 
Method Sens./spec.; 
PPV/NPV; 
Accuracy 
(%) 
 
Silverman 
2001  
(13) 
 
138 
 
97 AD 
41 non-AD 
 
2.9 
 
FDG-PET images: Visually rated by 
two experienced raters 
Pathology: criteria varied between 
sites 
 
94/73; 
89/83; 
88 
Foster 
2007 
(14) 
45 31 AD 
14 FTD                                                                                                                                                                                                                                                                                                                                                                                                                                    
6.2 FDG-PET images: Visually rated by 6 
neurologists with brief training
Pathology: NIA-Reagan 
98/73; 
88/91; 
89 
Jagust 
2007 
(15) 
44 25 AD  
19 non-AD 
3.6 FDG-PET images: Visually rated by 
two experienced raters 
Pathology: CERAD and NIA-Reagan 
84/74; 
81/78; 
80 
Minoshima 
2001 
(16) 
21 10 AD 
7 AD + DLB 
4 DLBD 
3.2 PET: automated 3D-sterotactiv 
surface projection, 12 predefined 
ROIs, normalized to pons. Uptake in 
primary visual cortex as discriminator. 
Pathology: Kachaturian, Lewy bodies 
90/80; 
82/90; 
86 
(for DLB 
and DLBD) 
Hoffman 
2000 
(17) 
19 13 AD 
6 non-AD 
2.5 FDG-PET images: Visually rated by 
one experienced rater 
Pathology: CERAD 
85/67; 
85/67; 
79 
CERAD: Consortium to Establish a Registry for Alzheimer’s Disease;  
NIA-Reagan: National Institute on Aging – Reagan Institute Criteria 
The sample in the study by Silverman et al is large in size, includes a heterogeneous group of 
dementia diseases, and most of the patients had dementia at a mild stage at the time of FDG PET 
scan. This study is thus the most interesting, and the sample size makes the estimated diagnostic 
values statistically meaningful. The 95 % confidence interval of the sensitivity was 89 – 99 %, and for 
the specificity it was 60 – 87 %.  
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Also Jagust et al and Hoffman et al diagnosed AD in heterogeneous groups, with several different 
dementia diseases and co-morbid conditions. The former study is also of a certain size, and the 
results are interesting and comparable with the study of Silverman. Worth mentioning is the fact that 
FDG PET provided the same diagnostic accuracy as clinical diagnosis 4 years later. It was also shown a 
substantial increase in positive and negative predictive values when FDG PET was added to the 
clinical evaluation, which is more likely to be the clinical context. The sensitivity of FDG PET was not 
within the confidence interval of the results by Silverman et al, and this could be explained by the 
visual evaluations of the raters of PET images or differences in sample size and composition.  
In the study of Foster et al there were only AD and FTD patients, and this was known by the 
neurologists assessing the PET images. The diagnostic values are still of some interest because also in 
the other studies, the outcome was AD or not AD. The 95 % confidence intervals were 94 – 100 % 
and 57 – 82 % for sensitivity and specificity, respectively. 
The studies of Minoshima et al and Hoffman et al are small and thus the diagnostic performances are 
of less general interest. Minoshima et al included co-morbid AD and DLB in the non-AD group, while 
in Silverman et al, Jagust et al and Hoffman et al AD co-morbid conditions were included in the AD 
group, when sensitivity and specificity were calculated. 
The study of Mosconi et al with multiple FDG PET scans and clinical evaluations provides valuable 
information of the connection between clinical symptoms, actual brain damage as visualized by FDG 
PET and at last verified by autopsy. It was seen that FDG PET images could show reduced glucose 
metabolism in the hippocampus several years before symptoms onset, and that at the MCI stage also 
parietotemporal and posterior cingulate cortices were involved. At the stage of AD, the frontal cortex 
could be affected.  
In general, the sensitivity is good and most AD patients could be correctly diagnosed using FDG PET 
at an early state. But due to a poorer specificity, several patients would incorrectly be diagnosed with 
AD, but in reality have other dementia diseases or in fact be cognitively normal (2/18 in Silverman et 
al). 
3.1.2 Longitudinal FDG PET studies of MCI subjects  
Most studies including more than 25 subjects are reviewed. The largest longitudinal study is within 
the ADNI project. Initially the major goal of the PET component of ADNI was to show that FDG-PET 
could serve as an outcome measure to track a drug effect with greater statistical power than routine 
clinical measures. A total of 404 subjects underwent FDG-PET scan at baseline, 368 after one year 
and 283 after 2 years. Most of the MCI subjects were PET scanned at 1.5 and 3 years as well (20). 
Several laboratories have analyzed the FDG-PET data, with different approaches.  
One study was performed by Landau et al on a subset of the ADNI sample (21). It included 85 MCI 
subjects who agreed to participate in all biomarker testing, which were FDG PET and structural MRI 
scans, CSF and blood samples and neuropsychological testing. The goal was to evaluate and compare 
the prognostic ability of glucose hypometabolism, hippocampal hypertrophy, CSF protein levels, 
APOE ε4 allele frequency and episodic memory performance, as measured by the Auditory Verbal 
Learning Test (AVLT). ROI-based data analysis was performed on the FDG-PET data, normalising the 
tracer uptake in these regions with a reference region comprised of cerebellar vermis and pons 
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The same kind of data from the other two ADNI subject groups, normal and AD, were used to 
establish the cut-off values for normal or abnormal measures. They were derived by performing 
Receiver Operator Characteristics (ROC) analyses optimizing on sensitivity and specificity. Then the 
cut-offs were used to categorize the MCI subjects as AD+ or AD- on each measure. The actual change 
of subject status from MCI to AD was established at the recruitment sites and reviewed centrally, and 
none of the parameters in the analysis of predictors were used as indicators of conversion. During 
the follow-up period of approximately 2 years, 28 of the 85 MCI patients converted to AD, with an 
annual rate of 17.2 %. None of the subjects converted to normal status or dementia of another type.  
In table 2 the performance of the different biomarkers as diagnostic tests on MCI subjects are listed. 
The FDG PET results are also listed in table 3 for comparison with other FDG PET studies. Knowing the 
number of converters versus non-converters, the positive (PPV) and negative predictive values (NPV), 
and the number of test positives and negatives for the different biomarkers, it is possible to derive 
sensitivities, specificities and accuracies. In the research article text, positive predictive value is 
defined as “the number of MCI converters correctly classified as AD+ divided by all the MCI 
converters”, which in fact is the definition of sensitivity. Likewise, the negative predictive value is 
incorrectly defined as specificity. It is assumed that this is just a textual error, and that the positive 
and negative predictive values are correctly calculated.  The other alternative would that these 
values in fact are the sensitivity and specificity, but then the 2-times-2 tables would not be coherent, 
which supports the first assumption. But this slightly reduces the trustworthiness of the numbers. 
Table 2.  Test performance of predicting AD conversion in MCI patients for the different biomarkers in 
the study of Landau et al (21). 
 FDG-PET 
 glucose 
metabolism 
MRI 
hippocampal 
volume 
CSF  
Aβ1-42 
AVLT   
episodic 
memory 
ApoE ε4 
 
PPV (%) * 
 
41 
 
41 
 
38 
 
41 
 
40 
NPV (%) * 79 78 76 88 74 
Test positive subjects ** 51 49 56 61 42 
Test negative subjects ** 34 36 29 24 43 
Sensitivity (%)  75 71 75 89 61 
Specificity (%) 47 49 39 37 56 
Accuracy (%) 56 56 51 54 58 
*From table 2 in Landau et al [34]. 
** From table e-1 in supplements of Landau et al, available at www.neurology.org. 
The episodic memory test score (AVLT) is by far the most sensitive in predicting conversion to AD in 
the MCI subjects, but the best accuracy was in fact achieved by the ApoE ε4 carrier status. FDG PET 
was more sensitive than hippocampal volume measurements, but the accuracy was the same. 
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By using Cox proportional hazard models to evaluate prediction, the authors found that only FDG-PET 
and AVLT was significant as predictors of conversion in a multivariate analysis, with hazard ratios of 
2.72 and 4.30 respectively. Combined hazard ratio was 11.7, which means that the subjects who 
were positive for both FDG-PET and AVLT had an almost 12 times higher risk of converting to AD than 
those who were negative on both. 
 In a mixed effect model, only CSF p-tau181p/Aβ1-42 ratio significantly predicted cognitive decline as 
measured by ADAS-Cog (Alzheimer’s Disease Assessment Scale – Cognitive Subscale) in multivariate 
analysis. It would have been interesting to compare this CSF ratio with the other biomarkers in table 
2, but this was not measured in all the MCI subjects, and the portion of converters and non-
converters for this MCI subgroup is not stated in the article or its supplements. Thus, the sensitivity, 
specificity and accuracy of CSF p-tau181p/Aβ1-42 ratio are unfortunately not possible to derive. 
The same research group also compared FDG-PET images and clinical status measured by the 
Functional Activities Questionnaire (FAQ) and ADAS-cog (22). The sample included approximately 400 
subjects in all three categories normal, MCI and AD subjects. They used continuous measures as 
predictors and outcome variables, rather than conversion/non-conversion status. Here it was found 
that both low baseline glucose metabolism and a longitudinal decline are sensitive to a decline of the 
ADAS-cog and FAQ score. 
Another research group also used a subset of the ADNI data to analyze the ability of structural MRI, 
FDG-PET and CSF proteins to predict future cognitive decline in MCI subjects (23). Walhovd et al 
analyzed data from baseline and the 2-year follow-up measurements in 36 normal controls, 51 MCI 
subjects and 25 AD patients. Values for grey matter thickness and glucose metabolism in 10 
predefined ROIs were calculated, in which effects of age and sex were regressed out. The PET activity 
in each ROI was normalized to the activity in pons. Baseline values from selected ROIs of MRI and 
FDG-PET were correlated with the changes in scores in MMSE, CDR-SB and a logic memory test 
(Wechsler Memory Scale – Revised) two years later. They found significant correlations between  
- baseline retrosplenial glucose metabolism (PET) and change in MMSE score  
- baseline retrosplenial thickness (MRI) and CDR-SB change,  
- baseline retrosplenial thickness (MRI) and MMSE, 
- baseline hippocampal volume (MRI) and change in WMS-R score, and 
- baseline entorhinal glucose metabolism (PET) and change in MMSE score, 
 
 in that order. They found no significant correlation between the CSF proteins ratio t-tau/Aβ42 and 
any of the clinical change measures, which in that respect is not in accordance with the previously 
described ADNI results by Landau et al [34]. This analysis did not include any rate of conversion from 
MCI to AD during the two-year follow up and predictive capability in that respect.  
A third approach was taken in analysis of the longitudinal FDG PET data of ADNI. Herholz et al used a 
fully automated voxel based method to calculate PET scores of the images of 44 normal controls, 94 
MCI subjects and 40 patients with mild AD, which had all undergone four PET scans during a two-year 
follow-up period (24). Thirty MCI subjects had converted to AD after two year. Also, seven MCI 
subjects reverted to a status as cognitively normal. Two of the control subjects progressed to MCI 
status. Abnormal PET score at baseline predicted conversion to a more severe diagnostic category 
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with sensitivity 57 % and specificity 67 %.The positive and negative predictive values were 45 % and 
77 %, respectively. This is lower sensitivity than what Landau et al got, but a higher specificity and 
accuracy (21). 
Mosconi et al reported a large longitudinal study following 77 initially normal subjects for a period 
averaging 9 years (25). At study end, 19 had declined to MCI, 6 were diagnosed AD and 5 had 
progressed to other dementia diseases. The decline to MCI and AD took place on average 8 years 
after baseline examination. All the six subjects who declined to AD received the MCI diagnosis after 
an average of 3 years after baseline. Both a ROI method with hippocampus and PCC and a voxel-
based analysis of the entire brain was used. Only hippocampal glucose metabolism was found to 
predict future cognitive decline in the normal subjects. At baseline the hippocampus metabolic rate 
was reduced 15 % in those who declined to MCI and 26 % in those who eventually were diagnosed 
AD.  It was 13 % lower in those who declined to a non-AD dementia. This indicates that hippocampal 
FDG-PET measures are sensitive to identify normal elderly at risk for cognitive decline.  
Anchisi et al followed 48 amnestic MCI subjects over a relatively short time period, and the results 
are summarized in table 3 (26). An important finding was that if the PET scan was not defined as 
abnormal, which meant regional uptake value ratio below a derived cut-off, the chance of converting 
to AD within the first year was only 3%.Those who converted within one year showed significant 
hypometabolism in the parietal and posterior cingulate cortex. Also, combining FDG PET and a verbal 
recall test (California Verbal Learning Test – Long Delay Free Recall), it was possible to enhance the 
prediction accuracy to 94 % compared to 85 % using FDG PET alone. Especially the specificity and 
positive predictive value were improved, to 97 % and 92 %, respectively, but on the expense of the 
sensitivity and negative predictive value, which were 86 % and 94 %, respectively. 
This effect was not seen in the study of Nobili et al, where the combination of FDG PET and tests of 
verbal episodic memory did not add any gain to the prediction of MCI subjects converting to AD 
compared to using only FDG PET (27). The results are listed in table 3. All MCI patients showed 
reduced glucose metabolism in the bilateral posterior cingulate cortex, left temporal pole and 
bilateral orbitofrontal cortex. The AD converters also had significantly less FDG uptake in the left 
lateral frontal cortex compared to the non-converters. 
Drzezga et al combined FDG PET results and ApoE ε4 genotype information from 30 MCI subjects, of 
whom 57 % were carriers (28). It was possible to achieve 100 % sensitivity in diagnosing AD based on 
baseline measurements, if test positivity was defined as either having abnormal FDG PET or an ApoE 
ε4 allele. Specificity was rather poor however, of 44 %. If being test positive meant both having 
abnormal PET scan and being ε4 gene carrier, the subjects were diagnosed with 100 % specificity and 
67 % sensitivity. The overall accuracies in these two approaches were reduced compared to FDG PET 
alone. Results of FDG PET alone are summarized in table 3. 
Looking more thoroughly into the MCI non-converters, Pagani et al divided this group into stable and 
declining MCI subjects (29). Of the initially 29 MCI subjects, 19 remained within that diagnostic 
category after an average follow-up period of about 20 months. Based on results from episodic 
memory tests, 9 were shown to be stable MCI subjects while 10 were declining in episodic memory. 
Their hypothesis was that of the 10 declining MCI subjects there are probably several late converters. 
PET images were analyzed by a voxel based method, and the three MCI subgroups were compared 
14 
 
with each other and images of 14 elderly controls. The MCI subjects that declined in episodic 
memory showed hypometabolism in the left hippocampus compared to the normal controls and the 
stable MCI subjects. The AD converters showed hypometabolism in the bilateral posterior cingulate 
cortex, the left parietal precuneus and the left fusiform gyrus compared to the controls. There was 
no significant difference between the control group and the stable MCI subgroup. And the MCI 
decliners showed no significant difference in glucose metabolism compared to the MCI subjects that 
converted to AD. 
Subcategories of MCI subjects have been studied longitudinally with FDG PET and clinical evaluations 
by Clerici et al (30). Fourteen amnestic MCI and 12 single domain non-amnestic MCI were followed 
up to 40 months. In the aMCI group, one remained MCI during the follow-up period, 12 converted to 
AD and one converted to LBD. In the snaMCI group, 3 subjects remained MCI, 3 converted to AD, 5 
converted to LBD and one to FTD. On average, the subjects received their dementia diagnosis 28 
months after the MCI diagnosis. Both groups showed significant hypometabolism in PCC, precuneus, 
the lingual gyri and frontal and temporal cortices compared to normal controls. When the two MCI 
groups were compared with each other, the aMCI group had a significantly lower metabolism in the 
left MTL, including the left hippocampus and fusiform gyrus.  
MCI subjects subcategorized into early- and late-onset MCI were followed for 5 years by Kim et al 
(31).  Seven of the 12 early-onset and 8 of the 14 late-onset MCI subjects converted to AD within the 
follow-up period, which gave approximately the same conversion rate of 57-58 %. The converters 
overall showed significant hypometabolism in posterior cingulate gyrus and frontal and 
temporoparietal areas compared to the controls. They also obtained significantly lower scores on a 
delayed verbal recall test. The early-onset converters showed significantly reduced metabolism in the 
left frontal areas compared to the non-converters. The same difference was seen among the late-
onset converters, but it was not significant. 
In table 3 the results from some of the longitudinal studies of MCI subjects are summarized. The 
table includes studies with emphasis on predicting conversion to AD by using FDG PET. The table is 
based on table 1 in (10), but all the content is reviewed and some information is added and edited 
compared to the original table. 
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Table 3. Summarized results of FDG PET studies of MCI subjects converting to AD. 
Study N Age  
± SD 
M/F Entry 
diag-
nosis; 
Mean
MMSE 
score 
Average 
follow-
up 
time 
(months) 
Con-
vert-
ers; 
Ann
ual 
rate 
(%) 
Sens./spec.; 
PPV/NPV; 
Accuracy 
(%) 
Data 
analysis 
Image 
scaling 
Discri-
minating 
brain 
area 
Herholz 
2011 
(24) * 
94 75 ± 8 66/28 aMCI 
27 
24 32; 
16 
57/67; 
45/77; 
64 
Automated 
VBA 
(PALZ/PMOD 
software 
package) 
Global Temporal 
and parietal 
lobes 
Landau  
2010 
(21) * 
85 78 ± 7 56/29 aMCI; 
27 
23 33; 
17 
75/47; 
41/79; 
56 
1 composite 
pre-defined 
ROI 
/ROC analysis 
/SPM5 
Pons and 
cere-
bellar 
vermis 
Bilateral 
angular gyri, 
bilateral PCC 
and left 
middle/in-
ferior 
temporal 
gyrus 
Anchisi  
2005 
(26) 
48 67 ± 8 25/23 aMCI; 
28 
12 
(median) 
29; 
29 
93/82; 
68/97; 
85 
SPM99/3 
volumes of 
interest/ROC 
analysis 
Sensori-
motor 
cortex 
Parietal 
cortex and 
PCC 
Nobili 
2008 
(27) 
33 76 ± 5 
 
13/20 aMCI ; 
27 
21 33; 
19 
82/91; 
82/91; 
88 
2x25 
predefined 
volumetric 
ROIs 
/Principal 
component 
analysis 
/Computerize
d Brain Atlas 
Global Bilateral PCC, 
left temporal 
pole and left 
lateral 
frontal 
cortex 
 
Drzezga  
2005 
(28) 
 
30 
 
70 ± 8 
 
14/16 
 
5 
aMCI, 
25 md-
aMCI; 
27 
 
16 
 
40; 
30 
 
92/89; 
85/94; 
90 
 
Neurostat/ 20 
predefined 
ROIs/ROC 
analysis 
 
Not 
specified 
 
PCC and 
temporopari
etal cortex 
* ADNI studies with probable sample overlap. 
The accuracy ranges from 56 – 90 %, the sensitivity from 57 – 93 % and specificity from 47 – 91 %. 
The least interesting parameter may be the positive predictive value. PPV is directly proportional to 
the prevalence of the disease, and in these research samples the prevalence is higher than in the 
normal population. A quantitative review found that annual AD conversion rate in MCI subjects is 
about 4 % in the community population and about 7 % in specialist settings (32). In table 3, the 
annual conversion rate ranges from 17 to 30 %, and thus the PPVs are artificially high. The NPV are in 
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these studies between 79 and 97 %, and would probably be high in the community population as 
well. 
The study of Herholz et al and Landau et al involves the largest number of MCI subjects and the 
longest follow-up period, and presumably therefore are the most trustworthy. But they also got the 
poorest results, with lower sensitivity, specificity and accuracy than the other studies. Herholz et al 
achieved better results than Landau et al, using a fully automated voxelbased method, even though 
these samples probably contain mostly the same subjects. The fact that ApoE ε4 allele carrier status 
provides the best test accuracy in Landau et al raises the question whether the analytical methods 
that were used were optimal. The cut-off value of FDG uptake ratio classifying subjects as FDG PET 
positive or negative were based on analysis of AD patients and normal controls in the study of 
Landau et al. In the studies of Anchisi et al, Nobili et al and Drzezga et al the cut-off value was 
determined based on data of the MCI subjects and normal controls, and maybe this partly explains 
the differences in accuracy, sensitivity and specificity. 
Even though average MMSE scores at baseline are comparable for the different studies, of 27-28 
points, there is a greater variation between the converters and non-converters in the study of 
Drzezga et al and Anchisi et al, of almost 2 points. In Landau et al and Nobili et al, there is an MMSE 
score difference of less than 1 point. Also having the highest annual conversion rates, Drzezga et al 
and Anchisi et al seem to have more subjects with more severe MCI in their samples, in which future 
AD probably is more evident. And the best results were achieved by Drzezga et al, with an accuracy 
of as much as 90 %. Nobili et al got a strong result in a sample population with annual conversion 
rate in the lower range and MMSE score difference of only 0.2 points between converters and non-
converters. They took a different approach in the image processing and statistical analysis, but it is 
hard to say whether that is a main factor in achieving the high prediction accuracy or not. 
The ADNI studies are unique in the sense that multiple methods of measuring possible AD pathology 
have been used in the same patients and several times over a time period, and thus provide a good 
way of comparing these methods in the sense of predicting Alzheimer’s disease early. Of the studies 
described here, only Landau et al and Walhovd et al included MRI measurements and CSF sampling in 
their studies (21;23). As seen from table 2, MRI was slightly less sensitive, a little more specific and 
just as accurate as FDG PET in predicting future conversion to AD in MCI subjects in the study of 
Landau et al. In multivariate analysis, only the episodic memory test and FDG PET were the significant 
variables regarding AD prediction, while the CSF ratio p-tau181p/Aβ1-42 were the only significant 
predictor of cognitive decline as measured by ADAS-Cog.  Also Walhovd et al found in their study, 
that retrosplenial metabolism measured by FDG PET showed the strongest correlation with cognitive 
decline, but also MRI measurements of retrosplenial thickness and hippocampal volume in MCI 
subjects showed significant correlations (23). It was not found any significant correlation between 
CSF protein levels and clinical deterioration, as Landau et al did. In the latter article, inconsistencies 
among studies in general are suggested to be due to methodological issues like image analysis 
techniques, statistical methods, different cut-off criteria and study designs. Another factor could be 
differences in the samples, for instance in the degree of cognitive impairment and rate of cognitive 
decline. Assuming there must be considerable sample overlap in these two studies, this is probably 
not an issue in this case.  
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Both Landau et al and Anchisi et al were able to enhance the AD prediction accuracy in MCI subjects 
by combining FDG PET and episodic memory test, while Nobili et al found no such effect (21;26;27). 
Pagani et al used episodic memory testing in order to classify a subgroup of the MCI non-converters 
as decliners, with the hypothesis that these subjects were slow converters (29). 
Only in the latter study of Landau et al, Herholz et al and Mosconi et al it was performed FDG PET 
scans also at follow-ups, and thus measuring the rate of change in glucose metabolism in MCI 
subjects (22;24;25). Herholz et al found a close correlation in the change in glucose metabolism and 
cognitive decline as measured by ADAS-cog, especially in the progressing MCI subjects. They also saw 
that there were 3 times higher variability in the ADAS-cog changes compared to FDG PET changes, 
and thus FDG PET thus would be a better parameter to measure cognitive decline in clinical trials. 
Landau et al found similar results, and also observed that there was a significant difference in the 
glucose metabolism decline in the medial temporal lobe and marginally in the posterior cingulate 
cortex in MCI subjects compared to normal controls. There was a greater annual rate of hippocampal 
FDG uptake reductions in the normal subjects that declined to MCI or AD compared to those that 
remained cognitively normal, in the study of Mosconi et al. This was also seen in the posterior 
cingulate cortex, but the difference was not significant between those who converted to MCI and 
those who remained normal. 
Reduced hippocampal metabolism was found to predict future development of AD in cognitively 
healthy subjects (25). Hippocampal hypometabolism was also seen in MCI subjects that did not 
convert to AD but were declining cognitively (29). These two studies by Mosconi et al and Pagani et al 
might point to hippocampal hypometabolism as an early predictor of AD. In the MCI subjects 
converting to AD within a few years, there is found hypometabolism in the posterior cingulate cortex, 
temporoparietal areas, and sometimes also in lateral frontal and orbitofrontal cortex.  
3.2 PET with 11C-Pittsburgh compound B  
11C-Pittsburgh compound B (PiB) is an analogue of thioflavin-T, an established histological stain for 
detecting β amyloid plaques. The hypothesis is that PiB PET images visualizes the fibrillar amyloid 
plaque in vivo, and this tracer is one of several developed for so-called amyloid imaging, and the 
most widely studied (33). 
In AD patients, increased PiB retention has been found in regions including the frontal cortex, 
anterior and posterior cingulate cortices, precuneus and striatum, while subcortical white matter, 
pons and cerebellum are relatively spared. Also a considerable amount of healthy controls show 
elevated PiB binding, between 20 and 30 % (33). Results are inconsistent whether these subjects 
show subtle signs of cognitive impairment or not, compared to those without increased levels. In 
many studies, cut-off values of PIB uptake are established, and PiB PET images are defined as positive 
or negative, in the sense of increased levels of amyloid plaques or not. How these cut-off values are 
calculated varies, and no consensus has been reached on what is an abnormal level of PiB uptake 
(33) . In a recent review, data from several research groups are combined and show that 96 % of 341 
clinically diagnosed AD patients, 59 % of 272 MCI subjects and 24 % of 651 cognitively healthy 
controls were PiB PET positive (34). PiB positivity is more common in ApoE ε4 carriers, compared to 
non-carriers (35).  
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The largest PiB PET study to date recently reported their findings at baseline (36). The Australian arm 
of the ADNI, called Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging performed PiB 
scans in 177 healthy controls, 57 MCI subjects and 53 mild AD patient.  Also MRI images were taken 
in order to calculate hippocampal, grey matter and ventricular volumes. Clinical and 
neuropsychological evaluations were done, including a battery of tests. Images were analyzed by ROI 
based method, and PIB uptake values in the frontal, superior parietal, lateral temporal, lateral 
occipital and anterior and posterior cingulate regions were averaged. Cut-off values defining 
abnormal measurements were established for hippocampal volume and PiB retention values. The 
healthy controls were not representative of the general population, because a higher number of 
ApoE ε4 carriers were selected. That gave a percentage of 43 %, which is about twice the normal 
prevalence. Among the MCI and AD subjects, 55 % and 69 % were ApoE ε4 carriers, respectively. 
The neocortical PiB binding was higher in the AD than in the MCI group, which again was higher 
compared to the normal controls. High PiB retention was found in 33 %, 68 % and 98 % of the 
healthy controls, MCI subjects and AD patients, respectively, and the uptake level differed 
significantly between the subject groups. In the healthy controls, PiB binding increased with age. 
There was no significant difference in memory scores between PiB positive and negative healthy 
controls. PiB binding was significantly greater in ApoE ε4 carriers in the healthy controls and MCI 
groups. In the AD subjects, PiB binding was greatest in the orbitofrontal and posterior cingulate 
cortices, precuneus, lateral temporal cortex and striatum, and the same pattern was seen in the 
healthy controls, but with less involvement of posterior cingulate cortex and precuneus. 
Hippocampal volume correlated with PiB binding in the MCI subjects and weakly in normal controls, 
also after non-partial volume correction of PET images, but not in the AD patients. Doing a 
voxelbased analysis on non-demented sub-groups (healthy controls and MCI subjects), it was found 
that both hippocampal grey matter volume and temporal PiB binding correlated with episodic 
memory deficits, and that these two parameters contributed independently (37). 
3.2.1 Longitudinal PiB PET studies including post-mortem neuropathologic assessment 
There are very few studies of people with both PiB PET imaging and neuropathologic assessment. 
Most of them are case studies, and none of them would be described here with the inclusion criteria 
of 20 subjects or more. Nevertheless, the few case reports and small studies are described below 
since they have some qualitative information about the association between PiB uptake and β 
amyloid aggregation  
The largest study reported so far, by Sojkova et al, was of one demented and 5 non-demented 
participants from the Neuroimaging Substudy of the Baltimore Longitudinal Study of Aging (38). At 
the time of the initial imaging, all the participants were clinically evaluated as free of dementia or 
MCI, but one of them had a CDR-SB score of 0.5 and another of 2.0. The latter subject progressed to 
a CDR-SB score of 4.5 and had 3 PiB images taken during the follow-up period. PET images were 
analyzed by ROI based method of 15 predefined regions in addition to cerebellum and 3 regions used 
in CERAD assessment. The uptake values were highest in the precuneus and posterior cingulate 
region in 5 of the subjects and in the superior frontal region in the remaining person. The 
neuropathologic examination took place from 2 months till more than 2 years after PET imaging were 
done. In two of the patients, there was good agreement between the PiB binding and the 
postmortem assessment. That was in one subject with negative PiB image and no neuritic plaques, 
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which is the finding taken into account in the CERAD criteria, and in the demented subject with high 
PiB uptake and moderate neuritic plaques. Setting the cut-off of PiB uptake ratio to 1.2, also two 
more of the subjects had PET images in agreement with the neuropathologic findings of moderate 
neuritic plaques.  One of the last two subjects had a high uptake ratio in precuneus, and also the 
mean value of 8 selected cortical regions was high, but only sparse neuritic plaques were found. 
Precuneus is not one of the regions examined according to CERAD criteria, but further investigation 
revealed high amount of Aβ load in precuneus and many diffuse plaques. Also vascular Aβ was found 
in this subject, and may have contributed to the elevated PiB binding. In the last subject the PET 
image was not PiB positive, but the neuropathologic examination showed moderate neuritic plaques. 
One possible explanation might be that there is a polymorphic Aβ, to which PiB does not bind. 
Another explanation could be the time lag of 2.4 years from the PET scan was taken and till the 
autopsy was performed. 
A patient diagnosed with mild DAT, had elevated total and phosphorylated tau181 and reduced Aβ1-42 
level in CSF, but one year prior to receiving the diagnosis, he underwent a PiB PET scan which was 
normal (39). Neuropathologic examination was done 2.5 years after the PiB PET scan. He had enough 
diffuse plaques to meet the Khachaturian criteria of AD, but the amount of neuritic plaques and 
tangles only sufficient for the CERAD criteria of “possible AD”. The authors of the case report raised 
the notion that since PiB binds poorly to amorphous cortical Aβ plaques, AD variants characterized by 
mainly diffuse plaques without substantial amount of fibrillar Aβ, will not be detected by PiB PET 
imaging. These patients may not receive the AD diagnosis from neuropathologic assessment either, 
depending on which neuropathologic criteria that are being used. 
Another case report described the findings from a 64-year-old patient with severe AD (40). PiB scan 
was taken 10 months prior to death, and the neuropathologic examination confirmed the diagnosis 
as “definite AD”, according to CERAD criteria. Samples of cortical brain tissue were collected and the 
Aβ level determined. It was found strong association with the corresponding ROIs showing elevated 
PiB uptake in the PET image. 
The first reported pathologic examination compared with PiB PET images was of a 76-year-old man 
with a clinical diagnosis of dementia with Lewy bodies (41). He underwent FDG and PiB PET scans 
about 2 years and 3 months prior to death, respectively. The FDG image showed reduced glucose 
metabolism in both temporal and parietal cortices and mild reduction in the left frontal lobe. The PiB 
image showed elevated binding in the posterior cingulate, precuneus, posterior parietal, middle and 
inferior temporal, insular, and lateral and orbital frontal cortices. He then had MMSE score of 25 and 
CDR of 1.0. The neuropathologic examination confirmed the diagnosis of dementia with Lewy bodies. 
Also findings characteristic of AD was found. There was moderate numbers of neurofibrillary tangles 
and amyloid β pathology, with severe cerebral amyloid angiopathy and moderate diffuse plaques. 
The overall frequency of plaques was low and met the CERAD criteria of “possible AD”. A possible 
conclusion was therefore that the PiB uptake in this case reflected the Aβ in cerebral vessels more 
than in the brain parenchyma. PiB does not bind to Lewy bodies or neurofibrillary tangles. Based on 
this case study, the question was raised that PiB retention does not only occur in AD patients, but 
also in elderly cognitively normal subjects with raised Aβ and at risk of developing AD, in MCI 
subjects, in subjects with cerebral amyloid angiopathy and patients with dementia of Lewy bodies 
with amyloid pathology. 
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3.2.2 Longitudinal PiB PET studies of MCI subjects 
There are only a few longitudinal studies in MCI subjects with PIB PET reported so far, and in most of 
them the follow-up period has been two years or less. The ability to predict AD conversion is 
summarized in table 4. 
Recently the first longitudinal results from the AIBL study in Australia were published, by Villemagne 
et al (42). It is the largest longitudinal PiB PET study of MCI subjects so far. At the first follow-up at 20 
months after baseline, 106 healthy controls, 65 MCI subjects and 35 DAT subjects were clinically 
reassessed, and 90 % of them also underwent a second PiB PET scan. These images were analyzed by 
ROI-based method, and a standardized uptake value (SUV) was calculated for each region, averaged 
across both hemispheres. Dividing with the cerebellar cortex SUV gave SUV ratios (SUVRs).   A 
neocortical SUVR was calculated as the average of area-weighted mean of frontal, superior parietal, 
lateral temporal, lateral occipital, and anterior and posterior cingulate regions. Hierarchical cluster 
analysis was used to derive a cut-off value of 1.5 for the neocortical SUVR as abnormal versus 
normal. Of the MCI group, 48 % had developed AD at 20-month follow-up, and another 6 % had 
developed other types of dementia. The converters showed significantly lower MMSE score, lower 
episodic memory scores, higher prevalence of ApoE ε4 carriers and higher PiB SUVR at baseline than 
non-converters. The ability of baseline PiB PET to predict AD conversion is summarized in table 4. 
Also, five healthy controls developed MCI and one developed AD during the first 20 months after 
baseline, of whom five had high PiB initially. The MCI and AD groups showed small but significant 
increase in PiB retention. A greater increase was seen in the milder AD patients compared to those 
with more severe dementia.  Also PiB positive healthy subjects showed a significant increase in PiB 
uptake. Seeing the three groups as one sample, carriers of at least on ApoE ε4 allele had three times 
higher increase in PiB binding than non-carriers. Even though there was a significant inverse 
correlation between episodic memory and PiB binding at baseline in MCI subjects and normal 
controls, no close relation was seen between cognitive decline and increase in PiB retention. 
In the second year of ADNI, a project was started up using PIB as PET tracer, because of its increasing 
importance as a biomarker (20). Jagust et al describes some early results after one year follow-up. Of 
the 103 subjects enrolled at 14 different sites, follow-up data existed for 80 subjects, including 17 
normal controls, 50 diagnosed with MCI and 13 with AD. The PIB-PET images were analyzed by an 
automated ROI method. SUVR was measured relative to cerebellar gray matter. An average was 
made of SUVRs of the four regions anterior cingulate cortex, frontal cortex, parietal cortex and 
precuneus, and this value was used in comparisons between subjects and to track longitudinal 
change. A subject was defined as PIB positive if average SUVR exceeded 1.50. At baseline, 47 % of the 
normal controls, 72 % of the MCI subjects and 89 % in the AD group were PIB positive. There were 
only small and insignificant changes in group average SUVR values after one year for all the three 
groups, but on individual basis 22 % of the PIB positives showed a significant change in PIB uptake, 
and 8 % of the PIB negatives. The report does not say if any of the MCI subjects converted to AD 
during this year, and if so, what the PIB status at baseline and longitudinal change was.  
In another report, PIB PET images and MRI data from ADNI and another longitudinal study, the Mayo 
Clinic Study of Aging, were analyzed as one sample, by Jack et al (43). This made a total of 61 
subjects, including 21 normal controls, 32 aMCI subjects and 8 AD subjects. They underwent clinical 
evaluation and PET and MRI scans twice, approximately one year apart. Diagnostic categories of the 
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subjects were set at consensus conferences, and 28 % of the MCI subjects progressed to an AD 
diagnosis. One of the cognitively normal subjects progressed to MCI status. An automated ROI 
method was used to analyze the PET images, and PIB ratio values were calculated by dividing median 
PIB uptake in a ROI with median uptake in cerebellar grey matter. PIB ratio values from the 
prefrontal, orbito-frontal, parietal, temporal, anterior cingulate and posterior cingulate 
cortices/precuneus were combined to a global cortical ratio. A global cortical ratio exceeding 1.50 
defined the subject as PIB positive. The two MRI scans of each subject were used to calculate 
ventricular expansion rate as a measure of brain atrophy. At baseline, 29 % of the normal subjects 
were PIB positive, 59 % of the MCI subjects were the same, and all but one of the AD subjects were 
PIB positive. Also in this study the average annual change in global cortical PIB ratio was small for all 
the three groups, and no significant difference between the groups were shown. The change was 
greater for the PIB positives than PIB negatives among the MCI subjects, but there was no such 
difference among the normal controls. The ventricular expansion rate was significantly different 
between the groups, and was greatest for the AD group and smallest for the group of normal 
controls. This implies an acceleration in atrophy rate as Alzheimer’s disease progresses. The 
ventricular expansion rate also correlated with the change in CDR-SB and MMSE, which was not the 
case for annual PIB PET change. There was no significant correlation between ventricular expansion 
rate and change in PIB uptake values. It is not reported whether the 8 MCI converters were PIB 
positive at baseline.  
Comparable results were found in another recent study (44). Koivunen et al studied twenty-nine MCI 
subjects and 13 controls with PIB PET, MRI and neuropsychometry at baseline, and it was repeated 
after 2 years in the MCI subjects. At follow-up, 17 (59 %) had converted to AD. Among the 
converters, 87 % were carriers of the ApoE ε4 allele, as compared to 25 % of the non-converters. The 
PET images were analyzed with both ROI method and VBA. The 10 predefined regions included 
anterior and posterior cingulate, lateral frontal, lateral temporal and parietal cortices, caudate 
nucleus, putamen, thalamus and pons. In general, PIB uptake values were higher at baseline in the 
MCI converters than in the non-converters, especially in the posterior cingulate cortex. However, 
only in the non-converters a significant increase in PIB uptake over the two-year period was found; in 
anterior and posterior cingulate cortices, temporal and parietal cortices and putamen. The PIB 
images were not classified as being PIB positive or negative, but high region-to-cerebellum ratios 
(more than 1.5) was more frequent at baseline in the MCI converters in certain regions. The posterior 
cingulate cortex region-to-cerebellum ratio was high in 94 % of the MCI converters, and the results of 
using this in predicting conversion to AD is given in table 4. Hippocampal atrophy was visually graded 
from 0 to 4 by an experience neuroradiologist blinded to the clinical results. Atrophy was present in 
both converters and non-converters at baseline, and it increased over the follow-up period. A 
suggested interpretation of these results is that PIB uptake increases early and changes relatively 
little as the disease progresses, whereas hippocampal hypertrophy is more related to disease 
severity. Also in this study the follow-up period is relatively short, and it is uncertain whether some 
of the non-converters, and more specifically those with high regional PIB uptakes, later will be 
diagnosed with AD. 
In another study by Okello et al, which was partly the same research group as Koivunen et al, the 
subjects were defined as being PIB positive if the PIB binding ratio compared to cerebellum was more 
than 2 standard deviations greater than the control mean in all six predefined ROIs (45). This 
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criterion was fulfilled by 55 %. The resulting ability of predicting conversion to AD is summarized in 
table 4. The converters showed higher PIB retention in all cortical brain regions. Those who 
converted to AD within 1 year had higher PIB retention values in anterior cingulate and frontal 
cortices compared to slow-converters and non-converters. 
Three different clinical subtypes of MCI have been studied longitudinally by Wolk et al (46). A group 
consisting of subjects categorized as either single domain amnestic MCI (sd-aMCI), multi-domain 
amnestic MCI (md-aMCI) or non-amnestic MCI (non-aMCI) was followed up to 3 years. The overall 
results from this study are given in table 4, seeing the whole sample as a group of MCI subjects. 
Subjects were classified as PIB positive if the regional uptake ratio was more than the 75 percentile 
of the values from a control group in one or more of seven selected ROIs. More than half of the 
subjects in each MCI subtype group were PIB positive, also the non-amnestic MCI subjects. Nearly all 
multi-domain amnestic MCI subjects were PIB positive (5/6).  Verbal delayed recall was significantly 
worse among the PIB positives. It was not a significant difference in grey matter loss in the medial 
temporal lobes (including the hippocampi) in PIB positive amnestic MCI subjects compared to 
negative subjects, but comparing with controls there was. Only subjects in the amnestic subgroups 
and only PIB positive subjects converted to AD during the follow-up period. 
In the first longitudinally study using PIB PET imaging , by Forsberg et al, both PIB and FDG PET scans 
were obtained from 21 MCI subjects (47). Also CSF samples were taken at baseline. The subjects 
were followed, and 33 % converted to AD during that period. ROI based analysis was used to quantify 
PIB and FDG uptake in frontal, parietal and temporal cortices, posterior cingulum and subcortical 
white matter. Eleven patients showed high PIB retention in the frontal, parietal and temporal 
cortices, defined as more than one standard deviation above the mean level in a control group. All 
the converters were amnestic MCI subjects, and they all had high PIB values. The converters differed 
as a group significantly from the non-converters with respect to higher PIB retention in the posterior 
cingulum, a higher percentage of the ApoE ε4 allele carriers (85 %), lower CSF Aβ42, lower MMSE 
test score and reduced episodic memory. Significant correlations were observed between CSF Aβ42 
and PIB retention in the frontal cortex and posterior cingulum. Also, PIB uptake in frontal and 
temporal cortices and posterior cingulum correlated negatively with episodic memory. There was no 
correlation between glucose metabolism and PIB retention in any of the brain regions, and FDG 
uptake did not differ significantly between converters and non-converters.  
One way of comparing these studies is to look at the capability of PiB PET as a diagnostic test for AD 
in MCI subjects. Values for sensitivity, specificity and positive and negative predictive values are 
derived from text, tables and figures presented in the articles, and they are listed in table 4. 
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Table 4. Summarized results of PIB PET studies of MCI subjects with respect to AD conversion. 
Study 
(Ref) 
N Age  
± SD 
M/F Entry 
diag-
nosis; 
Mean
MMSE 
Average 
follow-
up 
time 
(months) 
Con-
vert-
ers; 
Ann-
ual 
rate 
(%) 
Sens./spec.; 
PPV/NPV; 
Accuracy 
(%) 
Data 
analysis 
Image 
scaling 
Discri-minating 
brain 
area 
Villemag
ne et.al. 
2011 
(42) 
65 73 ± 9 36/29 MCI; 
27 
20 48; 
29 
97/56; 
67/95; 
75 
Both semi-
automated 
and fully 
automated 
ROI method 
Cere-
bellum 
Frontal, 
superior 
parietal, lateral 
temporal, 
lateral occipital, 
and anterior 
and posterior 
cingulate 
regions 
Okello 
et.al. 
2009 
(45) 
31 69 ± 7 19/12 aMCI; 
28 
32 48; 
18 
93/81; 
82/93; 
87 
Analyze and 
SPM99/six 
predefined 
ROIs and VBA 
Cere-
bellum 
Anterior 
cingulate,poste
rior cingulate, 
frontal, 
temporal, 
parietal and 
occipital 
cortices 
Koi-
vunen 
et.al. 
2011 
(44) 
29 71 ± 6 18/11 MCI; 
27 
24 59; 
30 
94/58; 
76/88; 
79 
Imadeus and 
SPM2/10 
predefined 
ROIs and VBA 
Cere-
bellum 
Posterior 
cingulate cortex 
Wolk 
et.al. 
2009 
(46) 
23 70 ± 9 
(of 26 
sub-
jects at 
base-
line) 
19/7 
(of 26 
sub-
jects at 
base-
line) 
12 sd-
aMCI, 
 6 md-
aMCI, 
5 non-
aMCI; 
27 
21 22; 
13 
100/56; 
38/100; 
83 
11 predefined 
ROIs/SPM5 
Cere-
bellum 
Frontal, 
anterior 
cingulate, 
precuneus, 
parietal, lateral 
temporal and 
lateral occipital 
cortices and 
occipital pole 
 
Forsberg 
et.al. 
2008 
(47) 
 
21 
 
63 ± 8 
 
8/13 
 
12 a-
MCI,  
9 non-
aMCI; 
28 
 
Not 
reported 
 
33; 
N/A 
 
100/71; 
64/100; 
65 
 
5 predefined 
ROIs 
 
Cere-
bellum 
 
Posterior 
cingulate cortex 
 
The accuracy ranges from 65 – 87 %, the sensitivity from 93 – 100 % and specificity from 56 – 81 %. 
As discussed earlier, the positive predictive value is of limited interest because it is proportional to 
the prevalence of AD in the cohorts, which is higher in these studies than in the community 
24 
 
population. But as a parameter for comparison of similar studies, it has some value. Mean age and 
mean MMSE score at baseline and annual conversion rate could say something about sample 
similarity. One could expect that higher mean age, lower mean baseline MMSE and high annual 
conversion rate implied more affected MCI subjects and thus easier to diagnose as early AD. 
Villemagne et al studied a sample of older subjects, with mean MMSE in the lower range, and also 
the converters and non-converters differed by 2 points on MMSE, and the annual conversion range 
was in upper range, of 29 %.But they got the poorest result in terms of accuracy. The sensitivity was 
very good, however, of 97 %. This is the most trustworthy result, due to the largest sample. Koivunen 
et al studied a smaller, but quite similar sample in terms of age, MMSE and conversion rate, and they 
got very much the same results. 
In general the sensitivities are high, but the specificities are quite low. In most cases the cut-off value 
categorizing the subjects as PiB positive or negative would have an impact on the sensitivity versus 
specificity, and they differed in the studies in table 4. Both Villemagne et al and Koivunen et al uses a 
regional-to-cerebellum cut-off value of 1.5, as well as Jagust et al and Jack et al. Cortical PiB ratio 
values above the 75 percentile were categorized as PiB positive by Wolk et al. Forsberg et al did not 
define any cut-off criteria, but only PiB binding in posterior cingulate cortex was significantly 
different between the converters and non-converters, and all the converters had PiB uptake greater 
than the mean value of 1.7 in this ROI. Okello et al compared each ROI uptake ratio in an MCI 
subjects with the mean value plus two standard deviations of the same ROI in the control subjects. If 
it was higher in all the six predefined ROIs, the MCI subject was classified as PiB positive. Okello et al 
got reasonably good specificity as well as sensitivity, and thus the highest accuracy, but to what 
extent this is due to the different approach in defining PiB positivity is difficult to determine. 
In many of the studies, selected predefined ROIs are averaged to a global cortical value of uptake 
ratio, and this is used in the analysis of PiB PET imaging. Other studies focus more on what ROIs are 
most affected in the MCI subjects. Both Okello et al and Koivunen et al found that the baseline PiB 
retention was most increased in the posterior cingulate cortex in the converters compared to 
controls. The latter study also observed a greater uptake in anterior cingulate and frontal cortices in 
those subjects that converted within a year. Comparing converters and non-converters, Forsberg et 
al saw that the posterior cingulate cortex was the only ROI with significant difference. 
In four of the described studies, the subjects underwent PiB PET scans also at follow-up.  Jagust et al 
reported that no significant increase in PiB binding was seen at follow-up measurements one year 
later on a group level. Koivunen et al found that there was a significant increase after two years in 
the non-converters in several cortical brain regions, including anterior and posterior cingulate 
cortices, parietal and temporal cortices and putamen, but no significant difference was seen in the 
MCI subjects converting to AD. Both Jack et al and Villemagne et al found small but significant 
increase in PiB retention. The former did not see any difference between cognitively normal, MCI or 
AD groups, but there was a greater annual change in PiB positive MCI subjects compared to those 
who were negative. Villemagne et al found that the difference was significant for the MCI and AD 
patients, and also for PiB positive cognitively normal subjects. Neither of the two studies found any 
significant difference in increase for specific regions of interest.  
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Villemagne observed that PiB change significantly correlated with MMSE decline seeing the whole 
sample as one, but not with change in episodic memory. Jack et al did not find any correlation 
between the PiB change and change of CDR-SB, but a possible relation with MMSE change was seen.  
PiB positive subjects achieved significantly worse score on verbal delayed recall test at baseline than 
PiB negative subjects in the study of Wolk et al (46). Forsberg et al found PiB binding in frontal, 
temporal and posterior cingulate cortices to correlate negatively with episodic memory performance 
(47).  
MRI-measurements of grey matter volume was done in three studies and compared with PiB PET as a 
biomarker. Jack et al and Koivunen et al could evaluate the change in volume over time because of 
repeated MRI scans at follow-ups, while Wolk et al only had clinical assessment at follow-up. Jack et 
al found that the rate of ventricular change was greatest for the AD group and least for the 
cognitively healthy group. In the MCI subjects, it was more pronounced in the PiB positive subjects. 
The rate of ventricular change was clearly inversely correlated with cognitive decline, as measured by 
CDS-SB and MMSE. Koivunen et al observed that baseline hippocampal atrophy was higher on the 
left side in the converters and on the right side in the non-converters compared to controls. After 
two years there was a significant increased hypertrophy on both sides in all MCI subjects. Wolk et al 
saw that the PiB positive amnestic MCI subjects had significant hippocampal atrophy compared to 
controls, while the PiB negative subjects did not. There were not reported any attempts of using the 
MRI measurements to predict subsequent conversion to AD in any of these studies. 
It was a significantly higher PiB uptake in ApoE ε4 carriers than in non-carriers in the cohort of 
Villemagne et al, particularly in the healthy subjects and the MCI patients. The PiB increase after 20 
months was 3 times larger in the carriers compared to the non-carriers. Of the MCI subjects 
converting to AD, 90 % were carriers of the gene, compared to 38 % of the non-converters and 31 % 
of the normal controls. In the study of Koivunen et al, 82 % of the converters and 25 % of the non-
converters were carriers, while Forsberg et al found the numbers to be 85 % of the converters and 57 
% of the non-converters. 
Only Forsberg et al included CSF sampling in their study, and it was seen a significant correlation 
between CSF Aβ1-42 levels and PiB retention in the frontal and posterior cingulate cortices. This was 
also the only study performing both FDG PET as well as PiB PET scans, but they found no correlation 
between glucose metabolism and PiB binding. 
None of the studies combined PiB binding values and other biomarker parameters in order to 
enhance the diagnostic accuracy of AD in the MCI patients.  
3.3 PET with 18F-Florbetapir 
The next activities of the PET core in ADNI will include the use of 18F-labeled florbetapir, also called 
18F-AV45, in amyloid imaging (20). At the same time point the subjects will also be studied with FDG-
PET, MRI and CSF and blood biomarkers. 
Results from a longitudinal study of PET imaging with florbetapir with neuropathologic assessment 
after death were recently published by Clark et al (48).  The subjects were terminal ill patients who 
were willing to undergo PET scan and donate their brains for research after death. Of the 35 subjects 
studied, 9 were cognitively normal, 3 had MCI, 17 were clinically diagnosed with AD and 6 with other 
26 
 
dementia disorders. The florbetapir PET images were visually rated from 0 (no amyloid) to 4 (high 
levels of cortical amyloid) by 3 nuclear medicine physicians, which were blinded to other information 
about the patients. The median rating served as outcome variable. Also a quantitative analysis was 
done, calculating cortical to cerebellar uptake ratio (SUVR) in 6 predefined regions of interest 
(frontal, temporal, parietal, anterior cingulate, posterior cingulate cortices and precuneus) plus 
cerebellum as reference region. From the same 7 regions, tissue blocks from both hemispheres were 
dissected and analyzed with respect to β amyloid aggregation and neuritic plaque density. In 
addition, a neuropathologic diagnosis was made using standardized criteria (CERAD and NIA-Reagan). 
It was found a good correlation between the SUVR value and postmortem measurement of amyloid 
for each region. The blinded visual reading of AD positive PET images (rating 2 – 4) and the 
neuropathologic diagnosis of AD (CERAD “definite” or “probable”) was in agreement in 18 of 19 
cases, whereas 16 of them were clinically diagnosed correctly with AD.  All 16 subjects that was 
neuropathologically diagnosed non-AD (CERAD “no” or “possible”) was rated florbetapir PET negative 
(rating 0-1) visually, but one of these had received a clinical diagnosis of AD. None of the 3 MCI 
subjects were positive on the PET scan or diagnosed with AD by the neuropathologic examination. 
Thus the overall accuracy of florbetapir was 97 % in diagnosing AD correctly. When all the 152 
individuals enrolled in the project are finally examined neuropathologically, the accuracy will be 
provided with stronger confidence.  Eight of the 20 authors had affiliations with the commercial 
manufacturer of florbetapir. The report was later commented on, regarding inter-rater variability in 
assessment of the PET scans (49). This information was not provided in the article, but was submitted 
to the US Food and Drug Administration (FDA) in a report for approval of florbetapir from the 
commercial manufacturer. It appears that the three raters only agreed on the same score in 17 % of 
the cases, and that in one fourth of the cases the disagreement would give different conclusions with 
respect to subjects being amyloid positive (score 2 – 4) or negative (score 0 – 1) (50). However, one 
can see from the published article that if the mean neocortical SUVR values are used with a cut-off 
value of 1.17 to categorize the subjects as florbetapir PET positive or negative, they are 100 % in 
accordance with the CERAD diagnoses (48). 
Longitudinal studies including MCI subjects are ongoing, but are yet not reported, other than briefly 
in a conference abstract (51). 
Fleisher et al pooled data from 4 registered phase I and II trials of florbetapir (52). That gave a total of 
210 subjects, including 82 cognitively normal volunteers, 60 MCI subjects and 68 patients with 
probable AD. A ROI analysis was performed on the florbetapir images, and mean regional-to-
cerebellar uptake ratios (SUVRs) were calculated for 6 predefined regions: medial orbital frontal, 
temporal, anterior and posterior cingulate, parietal lobe and precuneus. A global cortical mean SUVR 
was obtained by averaging these 6 SUVRs. The three different groups differed significantly with 
respect to the cortical mean SUVRs. In the healthy controls, the florbetapir binding increased linearly 
with age. In the AD and MCI groups, greatest uptake was seen in precuneus, the posterior cingulate, 
the parietal lobe and the temporal and frontal cortices. 
They derived a cut-off value defining florbetapir PET positive from the cohort of 19 
neuropathologically verified AD subjects described above (48). All of them had a cortical mean SUVR 
of 1.17 of more. Hence, the cut-off value for amyloid positive was set to this value. They also defined 
an amyloid negative cut-off value, based on a cohort of 46 young (age 18 – 40 years) that were all 
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ApoE ε4 non-carriers and therefore were very unlikely to have cortical amyloidosis. So the amyloid 
negative cut-off value was set to 1.08, which was the maximum cortical mean SUVR in this group. 
Thus 81 % of AD patients were florbetapir PET positive, 40 % of the MCI subjects and 21 % of the 
healthy controls. And 85 %, 47 % and 28 % of these groups, respectively, were above the florbetapir 
negative cut-off value. The hypothesis is that using the negative cut-off value, those individuals in the 
earliest stages of amyloid accumulation can be identified. Only longitudinal studies can answer that.  
3.4 PET with 18F-Florbetaben 
One other promising amyloid tracer is 18F-Florbetaben, also known as 18F-BAY-94-9172 or AV-1. 
Recently, Villemagne et al published results from a multicenter study involving 109 subjects, 
including 30 patients with AD, 20 MCI subjects, 32 controls, 11 patients with FTLD, 7 with DLB, 5 with 
Parkinson disease and 4 with vascular dementia (53). Neocortical florbetaben binding was expressed 
as the average SUVR of the area-weighted mean of the frontal, superior parietal, lateral temporal, 
lateral occipital and anterior and posterior cingulate ROIs. A cut-off value of 1.4 for cortical SUVR was 
calculated by hierarchical cluster analyses, to define the subjects as amyloid positive or negative. 
Also visual rating of the PET images by to nuclear medicine physicians was done. All AD patients 
except one were amyloid positive and showed greater florbetaben retention in the frontal and 
posterior cingulate cortex/precuneus and slightly less in the lateral temporal and parietal cortex. Also 
60 % of the MCI subjects and 16 % of the controls had elevated florbetapir uptake. In the MCI group, 
the posterior cingulate, parietal, temporal and frontal cortices and the striatum showed significantly 
higher levels compared to the control group. 
Comparable results were found by Barthel et al in a phase II diagnostic study involving 81 AD patients 
and 69 healthy controls (54). Of the AD patients, 81 % showed elevated levels of florbetaben, and 10 
% of the healthy controls did the same. In the AD patients all neocortical regions showed significantly 
higher uptake compared to the controls, and the posterior cingulate cortex was found to be the best 
discriminator.   
There have not been any published studies of the correlation of florbetaben PET imaging results and 
post-mortem neuropathological findings yet. An ongoing phase 3 trial will provide such results (55). 
So far no other longitudinal studies of florbetaben have been published either, only some preliminary 
results have been published in an abstract (56). 
3.5 PET with 18F-Flutemetamol 
Flutemetamol, also called 18F-GE-067 is the fluorine-derivative of PiB, and is expected to show the 
same qualities in imaging of amyloid β. 
In a study of 27 patients with AD, 20 amnestic MCI subjects and 15 elderly and 15 younger healthy 
controls, it was shown that flutemetamol PET images can discriminate patients with AD from normal 
controls with high sensitivity and specificity (57). The cut-off value defining uptake values as 
abnormal was calculated to be 1.56 based on values of the elderly healthy controls and the AD 
patients. It resulted in 93 %, 50 % and less than 1% of the AD patients, MCI subjects and elderly 
healthy controls being flutemetamol PET positive, respectively. The most significant differences in 
uptake value ratios between AD patients and elderly healthy controls were in the lateral frontal, 
lateral temporal, lateral parietal and posterior cingulate cortices and striatum. The uptakes of 
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flutemetamol and PiB in the same subjects were highly correlated in the same volumes of interest. In 
almost all regions, the linear regression slope was almost equal to 1, except in subcortical white 
matter and pons. This means that flutemetamol uptake is higher than that of PiB in white matter, as 
it is for all the 18F-labelled stillbenes. 
No truly longitudinal study with flutemetamol PET scans has been done, but images were taken of 7 
patients with normal pressure hydrocephalus that previously had undergone biopsy from the right 
frontal cortex (58). In all of the four subjects with abnormal images there was also found amyloid 
plaque pathology in the biopsy tissue.  The three normal scans were in patients with no evidence of 
Aβ pathology. Also there were found significant correlation between the estimated amount of 
amyloid β deposition in the biopsy samples and the flutemetamol uptake value ratio of the 
corresponding ROI in the PET images. 
3.6 PET with 18F-FDDNP 
FDDNP was the first amyloid imaging tracer reported, and has been shown to bind to both the 
extracellular β amyloid plaques and the intracellular neurofibrillary tangles (59). Results from a study 
of 25 patients with AD, 28 MCI subjects and 30 normal controls, showed that global FDDNP uptake 
discriminated the patient groups with better accuracy than FDG glucose metabolism and MRI 
estimated medial temporal volumes (60). The different groups had significantly different uptake 
values. Twelve subjects were followed longitudinally with a clinical assessment after 2 years. The 9 
subjects that were clinically stable had only small increases in global FDDNP binding. One healthy 
subject was reclassified to have MCI, and two MCI subjects had developed AD. In these three 
subjects there were seen greater increases in FDDNP uptake. One patient with AD died 14 months 
after baseline, and a neuropathological examination was performed. It showed good correspondence 
between regions with high concentrations of plaques and tangles and the regions with high FDDNP 
uptake on PET images. 
Another study, however, did not find significant differences between AD, MCI and normal controls on 
group level, only between the AD group and the normal controls (61).  The subjects underwent both 
PiB and FDDNP PET scans, and the global binding of PiB was nine-fold higher than of FDDNP. In the 
AD patients, the PiB uptake was increased in all the cortical regions, but with the smallest increase in 
the medial temporal lobe. This was the region with the highest uptake of FDDNP for all groups .This is 
possibly explained by the different distribution of senile plaques and neurofibrillary tangles in the 
brain. 
No larger longitudinal studies of FDDNP PET imaging have been reported. 
4 Discussion 
4.1 Summarizing and comparing PET studies 
The longitudinal studies previously described of FDG PET that followed the subjects until death and 
post-mortem neuropathologic assessments showed good agreement between the FDG uptake and 
autopsy findings. FDG PET is found to diagnose AD with a sensitivity ranging from 84 – 98 % and 
specificity from 67 – 80 %, which means that a large number of AD patients would be correctly 
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diagnosed by FDG PET scanning, but also there would be a considerable amount of subjects of false 
positives, because the method is not so specific.  
Mosconi et al saw that subjects could show glucose hypometabolism several years before the onset 
of symptoms, and Jagust et al experienced that FDG PET gave the same test results as clinical 
evaluation 4 years later (15;18), which indicates a capability of FDG PET to detect preclinical and early 
AD. FDG PET images of the AD subjects reveal glucose hypometabolism in the posterior cingulate 
cortex and temporoparietal areas. Also areas in the frontal cortex may be affected. Fisher et al 
observed asymmetry in half of the subjects, and most often the right hemisphere was hypometabolic 
(14). In the preclinical stage, hippocampal hypometabolism is an early finding in the small study of 
Mosconi et al (18).  
The other selection of FDG PET studies evaluated in this review is of MCI subjects, in whom FDG PET 
is used to diagnose early AD, and clinical evaluation of the disease stage (MCI or AD) at follow-up is 
the gold standard. Accuracies for the different studies range from 56 – 90 %, sensitivities from 57 – 
93 % and specificities from 47 – 91 %. The two largest studies are analyses of the ADNI data, with 85 
and 94 MCI subjects, and probably with substantial sample overlaps (21;24). The results achieved by 
Landau et al and Herholz et al are in the lower range and are surprisingly poor, compared to the 
earlier and smaller studies. Leaving these results out, the accuracies, sensitivities and specificities 
would range from 85 – 90 %, 82 – 93 % and 82 – 91 %, which are fairly good results. One would 
expect the largest studies to be the most trustworthy, but the fact that ApoE ε4 gene carrier status 
was the most accurate predictor makes one question the analytical approach.  If this finding is 
correct, it would be unexpected based on earlier studies. Researchers can apply for access to the 
ADNI database to analyze the different biomarker measurements, and hopefully more studies on this 
material will be published. Herholz et al achieved a better accuracy than Landau et al, 64 % versus 56 
%, and Walhovd et al and Landau et al concluded contrarily about whether CSF proteins significantly 
correlate with cognitive decline or not, indicating that differences in analytical methods have 
significant impact on the results (21;23;24).  
Both Landau et al and Herholz et al found a close correlation between the longitudinal decrease in 
glucose metabolism and cognitive decline (22;24). Also the variation was less compared to change in 
ADAS-Cog scores, and thus FDG PET is a better parameter for measuring cognitive decline in clinical 
trials. The greatest reduction in glucose metabolism was seen in the medial temporal lobe and 
posterior cingulate cortex in the MCI subjects. 
In the MCI subjects converting to AD during the follow-up period, there is found hypometabolism in 
the posterior cingulate cortex, temporoparietal areas, and sometimes also in lateral frontal and 
orbitofrontal cortex at baseline measurements. This is in accordance with the findings from the other 
FDG PET studies, of AD subjects eventually neuropathological examined. Reduced hippocampal 
metabolism was found to predict future development of AD in cognitively healthy subjects, and 
hippocampal hypometabolism was seen in MCI subjects that did not convert to AD but were 
declining cognitively (25;29). This further supports the hypothesis of hippocampal hypometabolism 
as an early predictor of later AD development.  
Reviewing the longitudinal studies of PiB PET leaves several questions about the ability to measure 
AD pathology in the form of fibrillar amyloid plaques. Unfortunately there are few studies of PiB PET 
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imaging and later post-mortem neuropathologic assessment of AD patients, only case studies are 
described. In some of these the findings are consistent, for instance high PiB uptake and moderate 
level of neuritic plaques, good correspondence between ROIs showing increased binding and brain 
areas with amyloid β, or subjects with negative PiB PET scan and sparse findings at autopsy (38;40).  
But there are also cases of inconsistent findings of PiB binding and neuropathology, and there is a 
need of studies of larger samples with AD patients, in order to fully understand what PiB PET is 
measuring. Probably PiB binds to fibrillar amyloid β, but it is uncertain to what extent other forms of 
amyloid β is imaged on PiB PET scans. For instance, it is discussed that PiB may bind to vascular 
amyloid plaques, which is present in cerebral amyloid angiopathy and often, but not always 
associated with AD (38;41). Also, to what extend PiB binds to polymorphic or diffuse plaques is 
discussed, as attempts of explaining false positive of false negative PiB PET scans (38;39). 
This uncertainty has consequences for the interpretation of PiB positivity in cognitively normal 
subjects and stable MCI subjects. Will these subjects eventually develop AD, or does PiB also bind to 
amyloid β not necessarily contributing to AD pathology? The longitudinal studies of PiB PET with 
clinical evaluation as gold standard do not answer this either, due to short follow-up periods of 1 – 2 
years. 
The prediction accuracy of PiB PET in diagnosing early AD in the MCI subjects ranges from 65 – 87 %, 
the sensitivity from 93 – 100 %, and specificity from 56 – 81 %. Generally, this sensitivity for PiB is 
good, and most of the patients that develop AD can be diagnosed at the MCI stage of the disease. 
The specificity is rather poor, but must be interpreted with caution. At this point of PiB PET research 
there is uncertainty about whether false positive subjects eventually will be diagnosed with AD also 
clinically, develop other dementia diseases or will remain stable. Longer follow-up periods would 
answer this.  
In several studies, the distribution of PiB binding is observed to be of bimodal distribution, either 
elevated or not, and most evident in the groups of cognitively normal and MCI subjects (34;62). Of 
the studies in this review, Villemagne et al observed bimodal distribution in the normal controls, and 
derived the cut-off value for PiB positivity based on this (42). Also Wolk et al found a bimodal 
distribution in the MCI group, while Jack et al reported of a continuous distribution in PiB retention 
(43;46).  There is yet no consensus of the cut off value defining positive versus negative PiB PET 
images, but there seems to be a trend in the latest and largest studies towards an uptake value of 1.5 
scaled to the cerebellar PiB binding (20;42-44). This cut-off value could of course have an impact on 
the levels of sensitivity and specificity.  
The posterior cingulate cortex seems to be the predefined ROI that in most studies show significant 
difference in PiB uptake when MCI converters are compared to normal controls or non-converting 
MCI-subjects (44;45;47). A significantly increase in PiB retention was seen in anterior cingulate and 
frontal cortices in the subjects that converted to AD within a year. 
Serial PiB PET scans were taken in four of the studies reviewed. Both Jagust et al and Jack et al found 
only small and not significant changes in PiB retention after one year, while Villemagne et al saw a 
significant increase in the MCI and AD groups as well as in the PiB positive normal controls 
(20;42;43). The increase was not significantly different among the clinical groups, but was 
significantly greater among PiB positive MCI subjects in Jack et al and among both PiB positive MCI 
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subjects and normal controls in Villemagne et al, compared to PiB negative subjects. There were no 
significant differences in retention increase for any specific regions of interest (42;43). Koivunen et al 
found that there was a significant increase after two years in the non-converters in several cortical 
brain regions, but no significant difference was seen in the MCI subjects converting to AD (44). 
There has been a hypothesis that PiB retention reaches a plateau early in the pathophysiologic 
development of AD, probably at a preclinical stage, and after that changes very little as the disease 
progresses (63). These studies are not contradictory to that hypothesis, but the results of Villemagne 
et al might indicate a small gradient in PiB retention change with time instead of an asymptotic 
curve, as pointed out in their article (42). 
The PiB retention change during 20 months correlated significantly with MMSE decline for the total 
sample, found by Villemagne et al, and there were seen a possible relation after only one year of 
follow-up by Jack et al. There were no correlations with change in episodic memory of CDR-SB scores 
(42;43).  
It was a significantly higher PiB uptake in ApoE ε4 carriers than in non-carriers, particularly in the 
healthy subjects and the MCI patients, and the PiB increase after 20 months was 3 times larger in the 
carriers compared to the non-carriers (42). Of the MCI subjects converting to AD, 82 – 90 % were 
carriers of the gene, compared to 25 – 57 % of the non-converters (42;44;47).  
It is attempting to compare the results of prediction capability of FDG PET and PiB PET, as 
summarized in table 3 and 4, respectively. The samples seem to be in the same range with respect to 
baseline mean MMSE, but the subjects of the FDG PET studies are in a higher age range. The annual 
conversion rates are comparable. Two of the FDG PET studies stand out because of considerable 
lower prediction ability, in terms of accuracy, sensitivity and specificity (21;24). These are also the 
largest studies, analyzing the ADNI data, and if these two studies are representative of what is 
possible to achieve in large cohorts, FDG PET is less accurate, less sensitive and less specific than PiB 
PET in predicting later conversion to AD in MCI subjects. If these two studies are not representative 
however and are excluded, the comparison of FDG and PiB PET indicate that PiB PET is more sensitive 
while FDG PET is more specific and also more accurate, see table 5. 
Table 5. Range of accuracy, sensitivity, specificity, PPV and NPV from studies of the two PET methods, 
summarized from table 3 and 4. 
 FDG PET PiB PET 
 ADNI studies Non-ADNI studies  
Accuracy 56 – 64 85 – 90 65 – 87 
Sensitivity 57 – 75 82 – 93 93 – 100 
Specificity 47 – 67 82 – 91 56 – 81 
PPV 41 – 45 68 – 85 38 – 82 
NPV 77 – 79 91 – 97 88 – 100 
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One cannot conclude based on this rough comparison, and optimally there should be longitudinally 
studies of both PET methods in the same subjects. Such data probably exists in the ADNI database, 
but no comparison analysis of FDG and PiB PET has been reported yet. Only one study of those 
reviewed here involved imaging with both FDG and PiB PET. Forsberg et al found no correlation 
between glucose metabolism and PiB binding (47). This is one of the smallest studies, of only 21 MCI 
subjects, and they did not find any significant difference in FDG uptake between converters and non-
converters either, in contrast to the other longitudinal FDG PET studies of MCI subjects described in 
this review. 
In both of the methods, there is no standardized method of setting the cut-off value defining 
abnormal versus normal images, and this is expected to have an impact on differences between 
studies in the diagnostic capability of early AD. 
In these studies reviewed, the accuracy is never 100 %. The accuracy shows to what extent the PET 
imaging results are in accordance with the clinical diagnosis at follow up evaluation, usually 1-3 years 
after the PET scan. When clinical evaluations are used as gold standard, it is hard to establish what 
part of the discrepancy from 100 % merely mirrors the uncertainty in the clinical diagnosis and what 
part is the uncertainty in the method itself. There is a hypothesis of cognitive reserve, which is meant 
to explain the differences in the degree of cognitive impairment for subjects with the same degree of 
AD pathology in the brain. For instance it is found that people with higher degree of education have 
more advanced AD pathology than those with less education at the same level of symptoms. This 
might be explained by a higher number of neurons and higher synaptic density (7). Cognitive reserve 
may also explain that younger MCI subjects show more extensive hypometabolism but obtain higher 
scores on neuropsychological tests than older subjects at the same stage of disease as measured by 
MMSE (31). Genetic vulnerability, life style factors and co-morbid conditions influence on the 
threshold for cognitive impairment caused by amyloid β aggregation. Clinical symptoms will reflect 
the degree of neuronal damage differently, and thus the clinical evaluation might not reflect the 
actual pathology. Cognitive reserve is not a factor in biomarker measurements.  
Also a comparison of the regional differences in tracer uptake between FDG and PiB in the same MCI 
subjects would provide interesting information. The posterior cingulate cortex seems to be most 
often affected in the MCI converters, in terms of both glucose metabolism and amyloid deposition. In 
the FDG PET studies also parietotemporal areas are often mentioned, while anterior cingulate cortex 
and frontal areas might seem more important in the PiB PET studies. The effect of atrophy will 
influence differently on FDG and PiB PET measurements, in the sense that glucose hypometablism 
will be more severe while PiB retention will be less pronounced. Partial volume corrections are 
sometimes performed in FDG PET studies to eliminate volume as confounding factor on glucose 
metabolism.  
In a study of 20 patients with mild AD, both longitudinal FDG and PiB PET imaging were performed 27 
months apart (64). Voxel-based analysis was performed on the images, and they compared the 
regional overlaps of the two methods by Dice similarity coefficients. FDG PET showed 
hypometabolism in bilateral parieto-temporal and posterior cingulate cortices and precuneus and 
right dorsolateral prefrontal cortex. At follow-up hypometabolism increased, especially in the right 
temporo-parietal cortex. At baseline PiB retention was seen in bilateral parieto-temporal and 
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posterior cingulate cortices and precuneus, as well as orbitofrontal, medial and lateral prefrontal 
cortices. This pattern did not change much at follow-up measurements. The strongest intermodal 
similarity was actually between the baseline PiB PET and the follow-up FDG PET patterns, of 47 %.  
One possible interpretation of this is that the changes of hypometabolism follow the pattern of 
amyloid depositions with a temporal delay, and that amyloid depositions precede the neuronal 
damage. But again, longitudinal studies of MCI subjects involving both PET modalities are necessary 
to further investigate this.  
There are also other tracers than PiB used in so-called amyloid imaging. The first amyloid tracer 
reported was the 18F-labeled tracer called FDDNP. This is thought to image neurofibrillary tangles as 
well as amyloid plaques. No larger longitudinal studies have been reported. The highest FDDNP 
binding is seen in the medial temporal lobe, which might be explained by a high density of 
neurofibrillary tangles in this region. It has been shown that global binding of PiB is nine-fold higher 
than of FDDNP in the same subjects (61). 
There are three 18F-labelled tracers currently in clinical trials, which are expected to become 
commercially available, namely florbetapir (AV-45), florbetaben (BAY-94-9172) and flutemetamol 
(GE-067). These are also thought to image amyloid plaques, and their physical half-life of 110 
minutes provides a practical advantage compared to 11C-PiB, with half-life of only 20 minutes. The 
18-F labeled tracers may thus be produced centrally and distributed to the PET centers, while PiB 
requires an on-site cyclotron for local production.  
Florbetapir will be included in the next phase of the ADNI project. One study including post-mortem 
neuropathologic assessment showed strong relation between the PET images and the autopsy 
findings (48). In MCI subjects and AD patients, the PET images show increased uptake of the 18F-
labelled tracers in precuneus, the posterior cingulate cortex, the parieto-temporal lobes and frontal 
cortex. The uptake is higher than that of PiB in white matter (52;53;57). No longitudinal studies 
involving MCI subjects are published yet, but are expected to come within the next years.  
4.2 Comparing with MRI methods 
Structural MRI imaging is used to measure volume or atrophy, cortical thickness or density of tissue 
compartments, for instance gray matter. Especially grey matter volume loss is often assessed. In AD, 
the medial temporal lobe is affected most, and the hippocampus can be reduced with 20 % already 
at a mild stage (34). The lateral temporal, parietal and prefrontal lobes also show volume losses, but 
to a lesser extent and more variably across studies. It has been shown that hippocampal hypertrophy 
and posterior cingulate gyrus atrophy is associated with increased PiB retention, also in cognitively 
normal subjects. Also cognitively normal carriers of the ApoE ε4 allele experience greater 
hippocampus volume loss than non-carriers.  
Of the FDG PET studies reviewed here, only two studies included MRI measurements (21;23). As seen 
from table 2, MRI was slightly less sensitive, a little more specific and just as accurate as FDG PET in 
predicting future conversion to AD in MCI subjects in the study of Landau et al. Walhovd et al found 
in their study that retrosplenial glucose metabolism measured showed the strongest correlation with 
cognitive decline, but also MRI measurements of retrosplenial thickness and hippocampal volume in 
MCI subjects showed significant correlations (23).  
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MRI-measurements of grey matter volume were done in three of the PiB PET studies. Serial MRI 
scans in the study of Jack et al showed that the ventricular change after one year was greatest for the 
AD group and least for the cognitively healthy group (43). In the MCI subjects, it was more 
pronounced in the PiB positive subjects. The rate of ventricular change was clearly inversely 
correlated with cognitive decline, as measured by CDR-SB and MMSE. Hippocampal atrophy was 
significantly increased after two years in all MCI subjects, in the study of Koivunen et al (44). Wolk et 
al saw that the PiB positive amnestic MCI subjects had significant hippocampal atrophy compared to 
controls, while the PiB negative subjects did not (46). MRI measurements were not used to predict 
subsequent conversion to AD in any of these studies. 
In a recent study of longitudinal MRI data from ADNI by Misra et al, spatial patterns of brain atrophy 
and changes with time are analyzed by high-dimensional pattern classification (65). The sample 
included 103 MCI patients, of which 27 converted to AD within the follow-up period of 15 months. 
The aim was to determine predictors of short-term conversion from MCI to AD. There were found 
significant differences at baseline between AD converters and non-converters, even though the 
average baseline MMSE score was about the same, of 26 – 27, in both groups. The converters had 
reduced grey matter volumes in a number of brain regions, including the anterior hippocampus, 
amygdala, much of the temporal lobe and the insular cortex, posterior cingulate and orbitofrontal 
cortex. Also white matter reductions were seen, primarily in the periventricular frontal region, 
indicating increased periventricular small-vessel pathology in the converters. The last tissue type 
analyzed was cerebrospinal fluid, which was larger in the temporal horns of the lateral ventricles 
bilaterally. There were no significant differences in the rate of change of grey matter between the 
two MCI groups. A pattern classification method enabled a score, which defined the MRI images as 
either positive for AD pathology or not. The best classification accuracy in terms of identifying 
converters and non-converters based on baseline MRI data was 82 %. Also several non-converters 
had a score value indicating AD pathology, and could be expected to develop clinical AD in the future. 
The authors suggest that vascular pathology ought to be studied in tandem with brain atrophy, and 
could be important in the issue of predicting which subjects will convert to AD.  
Also Ewers et al studied the ability of MRI measurements to predict conversion from MCI to AD 
based on longitudinal ADNI data. They used hippocampal volume and entorhinal cortex alone or in 
combination with CSF protein levels and neuropsychological tests (66). The sample consisted of 81 
patients with AD, of the 130 MCI subjects and 101 healthy controls. Of the MCI subjects, 58 
developed AD within the 3.3 years of clinical follow-up. Logistic regression analysis was used to 
discriminate the AD patients from the normal subjects, and then the model derived was applied to 
the MCI subjects, to predict AD conversion or not. In a second approach they tried the different 
combinations of biomarkers and neuropsychological tests to find the one that identified the 
converters and non-converters with the best accuracy, but limited to maximum 4 predictors. The 
best single-predictor was the right entorhinal cortex, with sensitivity of 53 %, specificity of 77 % and 
total accuracy of 69 %. Using four predictors, the best result was with the combination of right 
hippocampal volume, CSF p-tau181/Aβ, trail making test b (TMT-B) and age. This gave an accuracy of 
76 %, sensitivity of 88 % and specificity of 68 %. This increase in accuracy was not significant 
however, and the authors raise the notion that the increased number of measurements may not be 
justified in terms of accuracy enhancement. 
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These two longitudinal ADNI studies of structural MRI both achieve better results than hippocampal 
volume in the ADNI study of Landau et al, as seen in table 2. The accuracies of 56 %, 76 % and 82 % 
differ quite a lot, taken into account that there must be some sample overlaps, and the different 
analytical methods must play a significant role. Comparing the studies of Ewers et al and Landau et al 
(table 2), entorhinal cortical thickness was a less sensitive, more specific and more accurate predictor 
of future AD than glucose hypometabolism and hippocampal volume. Also compared with the other 
ADNI FDG PET study of Herholz et al (in table 3), the entorhinal cortical thickness was less sensitive 
but more specific and accurate than FDG uptake, but compared with the other FDG PET studies the 
results  of Ewers et al was poorer . The specificity of entorhinal cortical thickness seems to be in the 
same range as PiB PET, but is much less sensitive and thus less accurate than PiB PET, as seen in table 
5. 
Other MRI techniques like diffusion tensor imaging and functional MRI are expected to become more 
important in the early diagnostics of AD. MRI diffusion tensor imaging (DTI) is a technique that is 
used to measure microstructural changes in white matter fiber tracts. Fractional anisotropy (FA) is 
derived from the DTI data based on the movements of water molecules, and is a measure of fiber 
directionality and integrity. Mean diffusivity is the magnitude of the diffusion. In AD patients, the 
fibers connecting the hippocampus and posterior cingulate gyrus are impaired, and also fibers 
connecting the prefrontal cortex with the medial temporal lobe or the parietal cortex. Also 
cognitively healthy subjects with at least one ApoE ε4 allele show reduced FA in the posterior 
cingulum, corpus callosum and other major white matter bundles (34). 
In MCI subjects, it has recently been found that entorhinal white matter changes measured by DTI 
are significantly increased in amnestic MCI subjects compared to individuals with subjective memory 
complaints, but not fulfilling the MCI criteria, and that these changes were related to reduced story 
memory as measured by Wechsler Memory Scale – Revised (WMS-R) (67). Not many longitudinal 
studies of DTI measurements in MCI subjects has been published, but in a small study of 13 MCI 
subjects mean diffusivity in left hippocampus at baseline was significantly increased in the 6 subjects 
converting to AD within 19 months. Neither hippocampal FA nor volume differed significantly (68). In 
another small longitudinal study recently published, 14 amnestic MCI and 11 normal subjects were 
followed in 13 months (69). Only one of the MCI subjects converted to AD during this period. It was 
found no significant difference in baseline FA between the normal and the MCI subjects, and neither 
in FA decline. 
In functional MRI (fMRI), blood flow and blood oxygen level is measured, which is believed to show 
changes in neuronal activity within a few seconds (34). It can be used to both image brain activity 
while specific tasks are performed or during resting state. The last years a brain network termed the 
default mode network (DMN) has received attention in fMRI studies of AD patients and MCI subjects. 
The DMN includes the medial frontal, temporal and parietal brain regions, and is most active during 
periods of rest and less active during engagement in cognitive tasks. In AD patients, fMRI show 
abnormal activity in the DMN compared to cognitively healthy subjects, with impaired activation 
during rest and less deactivation during memory tasks. In a longitudinal study of 31 MCI subjects, 
fMRI images were taken during memory tasks at baseline (70). They were followed clinically for 2.4 
years, and 11 subjects converted to AD in this period. A quantitative DMN connectivity score was 
calculated, and this was significantly higher in the converters compared to the non-converters. It also 
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correlated with change in CDR-SB score. The DMN connectivity score did not significantly predict 
conversion when also baseline delayed verbal recall test results were taken into account. 
4.3 Combining several imaging and non-imaging biomarkers 
The last years there have been published studies using several imaging techniques and perhaps also 
neuropsychological tests, CSF sampling or ApoE ε4 genotyping within the same sample subjects. 
Especially the large multicenter studies like ADNI are providing such data. Usually the different 
modalities are analyzed individually and compared and correlated. Not so many studies combine the 
different methods to enhance the accuracy in determining diagnostic category (healthy controls, MCI 
subjects of AD patients) or predicting cognitive decline or conversion to AD in MCI subjects. 
It was found by Walhovd et al that logistic regression analysis with the combination of measurement 
data from FDG PET, MRI morphometry and diffusion tensor imaging (DTI) could place 44 MCI subjects 
and 22 controls in the correct diagnostic category with 100 % accuracy (71). A longitudinal follow-up 
will determine to what extent this combination predicts conversion to AD in the MCI subjects.   
Hinrichs et al used a fully multi-modal method incorporating all the different longitudinal 
measurements of AD pathology in ADNI (72). By using a method based on so-called Multi-Kernel 
Learning framework, they created a multi-modal disease marker to predict conversion from MCI to 
AD. The prediction capability is not given in numbers, but from one of the figures, this method 
seemed to identify very few of the converters, and definitely not providing better results than  what 
is seen for FDG PET or MRI alone. 
A kernel-based method was also used by Zhang et al to combine FDG PET, MRI and CSF 
measurements obtained from the ADNI database (73). The subjects included 51 AD patients, 99 MCI 
patients and 52 healthy controls. Within 18 months, 43 MCI subjects had converted to AD. Estimated 
grey matter volume and glucose metabolism are retrieved from 93 ROIs in both FDG PET and MRI 
images.  They found that 91 % of the AD converters in the MCI group and 73 % of the non-converters 
were correctly classified, which is the sensitivity and specificity, respectively.  The accuracy can be 
derived to be 81 %. These results are better than most of the other ADNI results presented here 
(21;24;66). Misra et al got a better accuracy though , of 82 %, in their MRI alone analysis (65). 
A few of the studies reviewed here combined FDG PET imaging with another biomarker to enhance 
the prediction ability. Jagust et al experienced in their longitudinal study of AD patients including 
post-mortem neuropathologic assessment that the positive predictive value of the clinical AD 
diagnosis initially increased from 70 % to 84 % if also the FDG PET image was interpreted as positive 
for AD, which is most likely the clinical setting. The negative predictive value increased from 65 % if 
the diagnosis initially was not AD to 83 % if also the FDG PET image was negative (15). 
Landau et al found that a combination of FDG PET and episodic memory, as measured by AVLT, 
predicted future AD conversion with the hazard ratio of nearly 12, compared to 2.7 and 4.3, 
respectively, for the two methods individually (21). Also Anchisi et al combined FDG PET and a verbal 
recall test to enhance prediction accuracy from 85 % to 94 %, and resulting in a sensitivity of 86 % 
and specificity of 97 % (26). Combining the FDG PET results and the ApoE ε4 genotype, Drzezga et al 
achieved 100 % sensitivity, defining those who were either FDG PET positive or ApoE ε4 carrier as 
test positive (28). The specificity was poor however, of 44 %. On the other hand, if test positivity was 
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defined to being both FDG PET positive and ApoE ε4 carrier, the specificity was 100 % and sensitivity 
67 %.  
These results of Drzezga et al are illustrated in the diagram in figure 1. All of those eight MCI subjects 
that were both FDG PET positive and ApoE ε4 carriers, seen in dark green in figure 1, developed AD. 
And none of those eight MCI subjects that were both FDG negative and ApoE ε4 non-carriers, as seen 
in white, developed AD. Of those five MCI subjects that were FDG PET positive but ApoE ε4 non-
carriers, colored in light green, three developed AD. Also one of the nine subjects that were FDG PET 
negative but ApoE ε4 carriers, in the blue section, progressed to AD.  
 
Figure 1. Illustrating the results of combining FDG PET and ApoE ε4 status by Drzezga et al (28). The 
study comprised 30 MCI subjects, of whom 12 developed AD. In total, 13 subjects were FDG PET 
positive and 17 were ApoE ε4 carriers. 
Only 30 MCI subjects were studied by Drzezga et al (28), but it seems reasonable that future 
conversion to AD could be predicted with good accuracy for subjects being positive on both 
measures, and that being negative on both would be predictive for not progressing to AD. Based on 
the good results achieved by Anchisi et al (26), one could think that for the two remaining groups in 
which FDG PET and ApoE ε4 carrier status points in opposite directions with regards to AD conversion 
(FDG PET positive/ApoE ε4 non-carrier and FDG PET negative/ApoE ε4 carrier), verbal delay test 
scores could distinguish probable converters from non-converters. Anchisi et al found a cut-off value 
for the California Verbal Learning Test (CVLT) by ROC analysis, and Landau et al did the same for AVLT 
(21). It would have been interesting to apply this approach of combining FDG PET, ApoE ε4 carrier 
status and verbal delay test scores on a larger sample of MCI subjects, like the already existing data 
from the ADNI project. 
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5 Concluding remarks 
The studies reviewed of FDG and PiB PET here show that conversion from MCI to AD can be 
predicted. What this means is that AD can be diagnosed by PET methods a few years before the 
clinical evaluation conclude with the same.  In general, sensitivities are good and especially for PiB 
PET. The specificity is poorer, but longer follow-up time will reveal if some of the “false positives” in 
fact will become “true positives”, because they decline cognitively at a slower rate. That would 
improve the specificity and accuracy. 
A hypothetical model describing the time development of the five most validated biomarkers was 
recently published (63). Also the connections between the biomarkers and the different 
neuropathologic processes are sought explained. Biomarkers of amyloid depositions are CSF Aβ 
reductions and increased binding of PiB as measured by PET. This occurs in a pre-clinical stage of the 
disease, probably several years before onset of the first symptoms. When MCI is a fact, these 
biomarkers are expected to show little change, and thus are not good biomarkers to monitor disease 
progression. Glucose hypometabolism as measured by FDG PET and CSF tau are supposed to be 
measures of synaptic dysfunction and neurodegeneration, respectively. These biomarkers will 
become abnormal somewhat later in the pre-clinical phase, and have a quite linear rate of change as 
cognitive function declines in the MCI phase. Structural MRI is thought to have a quite similar 
temporal course, but probably become abnormal even later in the pre-clinical phase. Structural MRI 
is a measure of atrophy as a result of neuronal death, and is expected to correspond well with the 
clinical expression of the disease. 
The results in the studies reviewed here are not contradictory to this model. This might also be 
expected, as the model is emerged from several of these and other studies. This model is evidently 
incorporated in the revised diagnostic criteria for AD of the U.S. National Institute on Aging (4), and it 
seems probable that this will prepare for the clinical use of biomarkers in the diagnostics of AD in the 
future. But for the time being there is a need of additional studies to confirm the hypothesis in the 
model. Additional biomarker comparison studies over longer time intervals and post-mortem 
assessments of the amyloid tracers will bring further clarity. Also standards for application of the 
biomarkers must be developed, and cut-off values defining normal versus abnormal must be 
established before employment in clinical settings. The large on-going multi-center studies will 
probably account for the greater part of this research. 
Clinical use of PET in early AD will also be depending on availability of PET centers and be an issue of 
costs. The new amyloid 18F-labelled tracers enhances the feasibility of amyloid imaging at smaller 
PET centers, because with their longer half-life compared to PiB, an on-site cyclotron will not be 
necessary.  
Lastly, there is also an ethical dimension in the clinical use of early biomarkers. As long as no 
treatment can reverse or stop the neurodegenerative process, it is probable not desirable to receive 
the diagnosis long before symptoms occur. Hopefully, such drugs will eventually come, and 
intervention will be more effective in an early phase, before irreversible neuronal damage has 
happened. Having the necessary diagnostic methods to correctly identify AD at a prodromal stage 
will then be of vast significance for the individuals affected, but also be of importance for the society 
as a whole, possibly reducing the number of elderly in need of institutional care. 
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Abbreviations 
 
Aβ Amyloid β 
APP amyloid precursor protein 
CERAD Consortium to establish a registry of Alzheimer’s      
disease 
AD Alzheimer’s disease 
DTI Diffusion tensor imaging 
DLB Dementia with Lewy bodies 
DLBD Diffuse Lewy body disease 
FDG [18F]Fluorodeoxyglucose  
fMRI Functional magnetic resonance imaging 
FTD Frontotemporal dementia 
LBD Lewy body dementia 
MCI Mild cognitive impairment 
MRI Magnetic resonance imaging 
MTL Medial temporal lobe 
PCA Principal component analysis 
PCC Posterior cingulate cortex 
PET Positron emission tomography 
PIB [11C]Pittsburgh compound B 
ROI Region of interest 
SPM Statistical parametric mapping 
VBA Voxelbased analysis 
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